| Symbol | BHC |
|---|---|
| Name | BAUSCH HEALTH COMPANIES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2150 SAINT ELZEAR BOULVARD WEST, LAVAL, Quebec, H7L 4A8, Canada |
| Telephone | +1 514 744-6792 |
| Fax | — |
| — | |
| Website | https://www.bauschhealth.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000885590 |
| Description | Bausch Health Companies Inc. is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars or guiding principles represent the foundation on which we are realizing our mission as an organization: People Quality Health Care Outcomes Customer Focus Innovation and Efficiency. Additional info from NASDAQ: |
2026-07-20 20:49
Lenar Aimee J. 🔴 sold 5.3K shares of Bausch Health Companies Inc. (BHC) at $4.83 Transaction Date: Jul 17, 2026 | Filing ID: 000101
Read more
2026-07-17 20:23
Lenar Aimee J. 🔴 sold 23.4K shares of Bausch Health Companies Inc. (BHC) at $4.89 Transaction Date: Jul 15, 2026 | Filing ID: 000099
Read more
2026-07-15 21:20
LEE STEVEN HYOSIG 🔴 sold 3.1K shares of Bausch Health Companies Inc. (BHC) at $4.75 Transaction Date: Jul 14, 2026 | Filing ID: 000097
Read more
2026-07-02 20:13
Director WECHSLER AMY B 🟢 acquired 1.4K shares of Bausch Health Companies Inc. (BHC) at $4.93 Transaction Date: Jun 30, 2026 | Filing ID: 000095
Read more
2026-07-02 20:11
Director Paulson John 🟢 acquired 12.7K shares of Bausch Health Companies Inc. (BHC) at $4.93 Transaction Date: Jun 30, 2026 | Filing ID: 000093
Read more
2026-07-02 20:10
Director LEUNG SANDRA 🟢 acquired 6.8K shares of Bausch Health Companies Inc. (BHC) at $4.93 Transaction Date: Jun 30, 2026 | Filing ID: 000091
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00347997 | A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix… | Na | Myopia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00347997 | A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix… | Na | Myopia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00375596 | A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunc… | Phase2 | Allergic Conjunctivitis | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00375596 | A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunc… | Phase2 | Allergic Conjunctivitis | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00548210 | Effectivity of Dermatix in Promoting Scar Maturation | — | Hypertrophic Scars | Unknown | — | — | ClinicalTrials.gov |
| NCT00624741 | Compassionate Use Study of Pergolide in Patients With Parkinson's Disease | — | Parkinson Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00624741 | Compassionate Use Study of Pergolide in Patients With Parkinson's Disease | — | Parkinson Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00548210 | Effectivity of Dermatix in Promoting Scar Maturation | — | Hypertrophic Scars | Unknown | — | — | ClinicalTrials.gov |
| NCT05976802 | Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Bu… | Phase4 | Ulcerative Colitis | Not_Yet_Recruiting | 2027-06-01 | 2030-01-01 | ClinicalTrials.gov |
| NCT05976802 | Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Bu… | Phase4 | Ulcerative Colitis | Not_Yet_Recruiting | 2027-06-01 | 2030-01-01 | ClinicalTrials.gov |
| NCT07717918 | A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants | Phase1 | Healthy | Recruiting | 2026-07-06 | 2026-08-01 | ClinicalTrials.gov |
| NCT07717918 | A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants | Phase1 | Healthy | Recruiting | 2026-07-06 | 2026-08-01 | ClinicalTrials.gov |
| NCT07722624 | A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ L… | Phase4 | Dry Eye | Recruiting | 2026-06-26 | 2026-08-30 | ClinicalTrials.gov |
| NCT07722624 | A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ L… | Phase4 | Dry Eye | Recruiting | 2026-06-26 | 2026-08-30 | ClinicalTrials.gov |
| NCT07723924 | This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-g… | Phase2 | Functional Constipation (FC) | Active_Not_Recruiting | 2026-06-01 | 2027-10-18 | ClinicalTrials.gov |
| NCT07723924 | This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-g… | Phase2 | Functional Constipation (FC) | Active_Not_Recruiting | 2026-06-01 | 2027-10-18 | ClinicalTrials.gov |
| NCT02129751 | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With … | Phase4 | Major Depressive Disorder | Not_Yet_Recruiting | 2026-06-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT02129751 | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With … | Phase4 | Major Depressive Disorder | Not_Yet_Recruiting | 2026-06-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07650708 | A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye … | Phase4 | Dry Eye Syndrome (DES) | Recruiting | 2026-05-05 | 2026-12-01 | ClinicalTrials.gov |
| NCT07650708 | A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye … | Phase4 | Dry Eye Syndrome (DES) | Recruiting | 2026-05-05 | 2026-12-01 | ClinicalTrials.gov |
| NCT06785194 | Revive Toric RWE Study | — | Astigmatism | Not_Yet_Recruiting | 2026-05-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT06785194 | Revive Toric RWE Study | — | Astigmatism | Not_Yet_Recruiting | 2026-05-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT07511387 | Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children | Na | Myopia | Active_Not_Recruiting | 2026-04-10 | 2027-03-01 | ClinicalTrials.gov |
| NCT07511387 | Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children | Na | Myopia | Active_Not_Recruiting | 2026-04-10 | 2027-03-01 | ClinicalTrials.gov |
| NCT07524946 | Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo | Phase4 | Acne Vulgaris | Not_Yet_Recruiting | 2026-04-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07524946 | Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo | Phase4 | Acne Vulgaris | Not_Yet_Recruiting | 2026-04-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07490535 | This is a Single Center, Open-label Prospective Study to Evaluate the Effect of… | Phase4 | Ocular Surface Disease | Not_Yet_Recruiting | 2026-03-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT07490535 | This is a Single Center, Open-label Prospective Study to Evaluate the Effect of… | Phase4 | Ocular Surface Disease | Not_Yet_Recruiting | 2026-03-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT07428538 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With… | Phase3 | Hepatitis | Recruiting | 2026-01-29 | 2028-02-01 | ClinicalTrials.gov |
| NCT07428538 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With… | Phase3 | Hepatitis | Recruiting | 2026-01-29 | 2028-02-01 | ClinicalTrials.gov |
| NCT07111013 | A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixe… | Phase3 | Dry Eye Disease | Withdrawn | 2025-12-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT07111013 | A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixe… | Phase3 | Dry Eye Disease | Withdrawn | 2025-12-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT06618547 | Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia… | Na | Myopia | Not_Yet_Recruiting | 2025-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT06618547 | Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia… | Na | Myopia | Not_Yet_Recruiting | 2025-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT07187297 | A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Ther… | Na | Wrinkle | Recruiting | 2025-10-31 | 2027-03-01 | ClinicalTrials.gov |
| NCT07187297 | A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Ther… | Na | Wrinkle | Recruiting | 2025-10-31 | 2027-03-01 | ClinicalTrials.gov |
| NCT07168902 | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle… | Phase2 | Glaucoma | Completed | 2025-10-24 | 2026-05-18 | ClinicalTrials.gov |
| NCT07168902 | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle… | Phase2 | Glaucoma | Completed | 2025-10-24 | 2026-05-18 | ClinicalTrials.gov |
| NCT07128628 | A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry … | Phase2 | Dry Eye Disease | Recruiting | 2025-10-24 | 2026-11-01 | ClinicalTrials.gov |
| NCT07128628 | A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry … | Phase2 | Dry Eye Disease | Recruiting | 2025-10-24 | 2026-11-01 | ClinicalTrials.gov |
| NCT07214272 | A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Re… | Na | Skin Resurfacing | Active_Not_Recruiting | 2025-10-17 | 2026-09-01 | ClinicalTrials.gov |
| NCT07214272 | A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Re… | Na | Skin Resurfacing | Active_Not_Recruiting | 2025-10-17 | 2026-09-01 | ClinicalTrials.gov |
| NCT07205107 | Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel i… | — | Acne Vulgaris | Active_Not_Recruiting | 2025-10-02 | 2026-08-01 | ClinicalTrials.gov |
| NCT07205107 | Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel i… | — | Acne Vulgaris | Active_Not_Recruiting | 2025-10-02 | 2026-08-01 | ClinicalTrials.gov |
| NCT06978244 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Conce… | Phase1 | Ocular Pain | Active_Not_Recruiting | 2025-07-29 | 2026-11-01 | ClinicalTrials.gov |
| NCT06978244 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Conce… | Phase1 | Ocular Pain | Active_Not_Recruiting | 2025-07-29 | 2026-11-01 | ClinicalTrials.gov |
| NCT07054606 | A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear | Phase4 | Dry Eye | Completed | 2025-07-02 | 2025-11-03 | ClinicalTrials.gov |
| NCT07054606 | A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear | Phase4 | Dry Eye | Completed | 2025-07-02 | 2025-11-03 | ClinicalTrials.gov |
| NCT06620562 | Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-r… | Phase4 | Obesity; Drug | Recruiting | 2025-06-04 | 2028-08-01 | ClinicalTrials.gov |
| NCT06620562 | Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-r… | Phase4 | Obesity; Drug | Recruiting | 2025-06-04 | 2028-08-01 | ClinicalTrials.gov |
| NCT06803654 | A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic So… | Phase3 | Ocular Redness | Completed | 2025-05-22 | 2025-06-29 | ClinicalTrials.gov |
| NCT06803654 | A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic So… | Phase3 | Ocular Redness | Completed | 2025-05-22 | 2025-06-29 | ClinicalTrials.gov |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | Phase1 | Breast Cancer | Recruiting | 2025-03-11 | 2027-11-01 | ClinicalTrials.gov |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | Phase1 | Breast Cancer | Recruiting | 2025-03-11 | 2027-11-01 | ClinicalTrials.gov |
| NCT06718686 | Rifaximin SSD in Dementia Trial | Phase1 | Dementia Alzheimer Type | Recruiting | 2024-12-30 | 2027-12-30 | ClinicalTrials.gov |
| NCT06718686 | Rifaximin SSD in Dementia Trial | Phase1 | Dementia Alzheimer Type | Recruiting | 2024-12-30 | 2027-12-30 | ClinicalTrials.gov |
| NCT06594185 | A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire … | Na | Cataract | Completed | 2024-08-29 | 2025-05-21 | ClinicalTrials.gov |
| NCT06594185 | A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire … | Na | Cataract | Completed | 2024-08-29 | 2025-05-21 | ClinicalTrials.gov |
| NCT06479148 | Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens | Na | Cataract | Terminated | 2024-08-15 | 2024-12-12 | ClinicalTrials.gov |
| NCT06479148 | Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens | Na | Cataract | Terminated | 2024-08-15 | 2024-12-12 | ClinicalTrials.gov |
| NCT06333015 | Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF … | Na | Cataract | Active_Not_Recruiting | 2024-08-07 | 2026-07-01 | ClinicalTrials.gov |
| NCT06333015 | Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF … | Na | Cataract | Active_Not_Recruiting | 2024-08-07 | 2026-07-01 | ClinicalTrials.gov |
| NCT06565650 | A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry… | Phase4 | Dry Eye | Active_Not_Recruiting | 2024-07-31 | 2025-11-01 | ClinicalTrials.gov |
| NCT06565650 | A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry… | Phase4 | Dry Eye | Active_Not_Recruiting | 2024-07-31 | 2025-11-01 | ClinicalTrials.gov |
| NCT06809166 | Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight… | Phase4 | Obesity | Recruiting | 2024-07-04 | 2026-07-31 | ClinicalTrials.gov |
| NCT06809166 | Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight… | Phase4 | Obesity | Recruiting | 2024-07-04 | 2026-07-31 | ClinicalTrials.gov |
| NCT06527274 | Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization | Na | Nearsightedness | Active_Not_Recruiting | 2024-06-25 | 2025-03-30 | ClinicalTrials.gov |
| NCT06527274 | Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization | Na | Nearsightedness | Active_Not_Recruiting | 2024-06-25 | 2025-03-30 | ClinicalTrials.gov |
| NCT06333028 | A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Under… | — | Cataract | Completed | 2024-05-30 | 2025-03-13 | ClinicalTrials.gov |
| NCT06333028 | A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Under… | — | Cataract | Completed | 2024-05-30 | 2025-03-13 | ClinicalTrials.gov |
| NCT06346340 | A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry a… | Phase4 | Dry Eye | Completed | 2024-04-30 | 2025-02-24 | ClinicalTrials.gov |
| NCT06346340 | A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry a… | Phase4 | Dry Eye | Completed | 2024-04-30 | 2025-02-24 | ClinicalTrials.gov |
| NCT06309953 | A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry E… | Phase4 | Dry Eye | Completed | 2024-02-28 | 2024-06-17 | ClinicalTrials.gov |
| NCT06309953 | A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry E… | Phase4 | Dry Eye | Completed | 2024-02-28 | 2024-06-17 | ClinicalTrials.gov |
| NCT06053736 | 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses | Na | Refractive Ametropia | Completed | 2023-10-04 | 2023-12-15 | ClinicalTrials.gov |
| NCT06053736 | 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses | Na | Refractive Ametropia | Completed | 2023-10-04 | 2023-12-15 | ClinicalTrials.gov |
| NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exte… | Phase4 | Ulcerative Colitis | Recruiting | 2023-09-29 | 2027-06-01 | ClinicalTrials.gov |
| NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exte… | Phase4 | Ulcerative Colitis | Recruiting | 2023-09-29 | 2027-06-01 | ClinicalTrials.gov |
| NCT06052150 | Oral Health In Cirrhosis of the Liver (ORACLE) | — | Cirrhosis | Active_Not_Recruiting | 2023-09-18 | 2026-12-31 | ClinicalTrials.gov |
| NCT06052150 | Oral Health In Cirrhosis of the Liver (ORACLE) | — | Cirrhosis | Active_Not_Recruiting | 2023-09-18 | 2026-12-31 | ClinicalTrials.gov |
| NCT06060041 | IC-8 Apthera IOL New Enrollment Post Approval Study | — | Cataract | Recruiting | 2023-09-08 | 2027-09-30 | ClinicalTrials.gov |
| NCT06060041 | IC-8 Apthera IOL New Enrollment Post Approval Study | — | Cataract | Recruiting | 2023-09-08 | 2027-09-30 | ClinicalTrials.gov |
| NCT06098937 | Kalifilcon A Toric Compared to Commercially Available Lenses | Na | Astigmatism | Completed | 2023-09-05 | 2023-09-27 | ClinicalTrials.gov |
| NCT06098937 | Kalifilcon A Toric Compared to Commercially Available Lenses | Na | Astigmatism | Completed | 2023-09-05 | 2023-09-27 | ClinicalTrials.gov |
| NCT05723770 | Effects of NOV03 on the Tear Film | Phase4 | Dry Eye Disease (DED) | Completed | 2023-08-14 | 2023-12-23 | ClinicalTrials.gov |
| NCT05723770 | Effects of NOV03 on the Tear Film | Phase4 | Dry Eye Disease (DED) | Completed | 2023-08-14 | 2023-12-23 | ClinicalTrials.gov |
| NCT06069609 | Orientation Characteristics of Daily Disposable Toric Contact Lenses | Na | Astigmatism | Completed | 2023-08-11 | 2023-08-15 | ClinicalTrials.gov |
| NCT06069609 | Orientation Characteristics of Daily Disposable Toric Contact Lenses | Na | Astigmatism | Completed | 2023-08-11 | 2023-08-15 | ClinicalTrials.gov |
| NCT05984290 | Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in… | Na | Myopia | Completed | 2023-07-11 | 2024-06-27 | ClinicalTrials.gov |
| NCT05984290 | Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in… | Na | Myopia | Completed | 2023-07-11 | 2024-06-27 | ClinicalTrials.gov |
| NCT05815758 | Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ke… | Phase3 | Allergic Conjunctivitis | Completed | 2023-04-20 | 2023-09-18 | ClinicalTrials.gov |
| NCT05815758 | Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ke… | Phase3 | Allergic Conjunctivitis | Completed | 2023-04-20 | 2023-09-18 | ClinicalTrials.gov |
| NCT05565937 | A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and… | Na | Refractive Ametropia | Completed | 2023-04-12 | 2024-02-28 | ClinicalTrials.gov |
| NCT05565937 | A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and… | Na | Refractive Ametropia | Completed | 2023-04-12 | 2024-02-28 | ClinicalTrials.gov |
| NCT05591755 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults Wit… | Phase3 | Seasonal Allergic Conjunctivitis | Completed | 2022-11-18 | 2023-08-09 | ClinicalTrials.gov |
| NCT05591755 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults Wit… | Phase3 | Seasonal Allergic Conjunctivitis | Completed | 2022-11-18 | 2023-08-09 | ClinicalTrials.gov |
| NCT05264623 | Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for L… | Na | Hyperopia | Active_Not_Recruiting | 2022-11-15 | 2026-11-20 | ClinicalTrials.gov |
| NCT05264623 | Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for L… | Na | Hyperopia | Active_Not_Recruiting | 2022-11-15 | 2026-11-20 | ClinicalTrials.gov |
| NCT05660577 | Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact… | Na | Myopia and Hyperopia and Presbyopia | Completed | 2022-11-07 | 2023-01-16 | ClinicalTrials.gov |
| NCT05660577 | Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact… | Na | Myopia and Hyperopia and Presbyopia | Completed | 2022-11-07 | 2023-01-16 | ClinicalTrials.gov |
| NCT05608499 | Duobrii Treatment of Acne Keloidalis Nuchae (AKN) | Phase3 | Acne Keloidalis Nuchae | Terminated | 2022-10-26 | 2024-04-15 | ClinicalTrials.gov |
| NCT05608499 | Duobrii Treatment of Acne Keloidalis Nuchae (AKN) | Phase3 | Acne Keloidalis Nuchae | Terminated | 2022-10-26 | 2024-04-15 | ClinicalTrials.gov |
| NCT05579730 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treat… | Phase3 | Allergic Conjunctivitis | Completed | 2022-10-12 | 2023-07-22 | ClinicalTrials.gov |
| NCT05579730 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treat… | Phase3 | Allergic Conjunctivitis | Completed | 2022-10-12 | 2023-07-22 | ClinicalTrials.gov |
| NCT05505292 | Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Weare… | Phase4 | Dry Eye | Completed | 2022-09-22 | 2023-05-15 | ClinicalTrials.gov |
| NCT05505292 | Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Weare… | Phase4 | Dry Eye | Completed | 2022-09-22 | 2023-05-15 | ClinicalTrials.gov |
| NCT05297448 | Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patie… | Phase3 | Hepatic Encephalopathy | Active_Not_Recruiting | 2022-08-03 | 2026-01-01 | ClinicalTrials.gov |
| NCT05297448 | Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patie… | Phase3 | Hepatic Encephalopathy | Active_Not_Recruiting | 2022-08-03 | 2026-01-01 | ClinicalTrials.gov |
| NCT05360784 | "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in A… | Phase3 | Ocular Redness | Completed | 2022-05-13 | 2022-11-23 | ClinicalTrials.gov |
| NCT04140279 | A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.02… | Phase4 | Ocular Hypertension | Withdrawn | 2022-05-13 | 2023-08-01 | ClinicalTrials.gov |
| NCT04140279 | A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.02… | Phase4 | Ocular Hypertension | Withdrawn | 2022-05-13 | 2023-08-01 | ClinicalTrials.gov |
| NCT05360784 | "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in A… | Phase3 | Ocular Redness | Completed | 2022-05-13 | 2022-11-23 | ClinicalTrials.gov |
| NCT05071716 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encep… | Phase3 | Hepatic Encephalopathy | Active_Not_Recruiting | 2022-04-07 | 2025-09-01 | ClinicalTrials.gov |
| NCT05071716 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encep… | Phase3 | Hepatic Encephalopathy | Active_Not_Recruiting | 2022-04-07 | 2025-09-01 | ClinicalTrials.gov |
| NCT05075746 | Retrospective Chart Review of enVista Toric 0.9D Intraocular Lenses | — | Corneal Astigmatism | Completed | 2022-03-08 | 2023-01-03 | ClinicalTrials.gov |
| NCT05075746 | Retrospective Chart Review of enVista Toric 0.9D Intraocular Lenses | — | Corneal Astigmatism | Completed | 2022-03-08 | 2023-01-03 | ClinicalTrials.gov |
| NCT05325931 | 1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compar… | Na | Presbyopia | Completed | 2022-02-25 | 2022-03-28 | ClinicalTrials.gov |
| NCT05325931 | 1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compar… | Na | Presbyopia | Completed | 2022-02-25 | 2022-03-28 | ClinicalTrials.gov |
| NCT05320042 | 1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to U… | Na | Myopia | Completed | 2022-02-14 | 2022-05-10 | ClinicalTrials.gov |
| NCT05320042 | 1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to U… | Na | Myopia | Completed | 2022-02-14 | 2022-05-10 | ClinicalTrials.gov |
| NCT05129124 | Insertion Clinical Study to Evaluate the Orientation Characteristics of Multipl… | Na | Astigmatism | Completed | 2021-11-30 | 2022-01-13 | ClinicalTrials.gov |
| NCT05129124 | Insertion Clinical Study to Evaluate the Orientation Characteristics of Multipl… | Na | Astigmatism | Completed | 2021-11-30 | 2022-01-13 | ClinicalTrials.gov |
| NCT05027282 | Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm … | Na | Photoaging | Completed | 2021-10-27 | 2022-11-18 | ClinicalTrials.gov |
| NCT05027282 | Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm … | Na | Photoaging | Completed | 2021-10-27 | 2022-11-18 | ClinicalTrials.gov |
| NCT05422742 | Influence of SRP With MM on the Composition and Functional Characteristics of S… | Na | Periodontitis | Active_Not_Recruiting | 2021-10-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT05422742 | Influence of SRP With MM on the Composition and Functional Characteristics of S… | Na | Periodontitis | Active_Not_Recruiting | 2021-10-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT05126953 | 2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solutio… | Na | Contact Lens Wearer | Completed | 2021-09-21 | 2021-09-23 | ClinicalTrials.gov |
| NCT05126953 | 2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solutio… | Na | Contact Lens Wearer | Completed | 2021-09-21 | 2021-09-23 | ClinicalTrials.gov |
| NCT07090044 | Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac … | Phase4 | Vein Occlusion | Completed | 2021-08-20 | 2022-12-08 | ClinicalTrials.gov |
| NCT07090044 | Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac … | Phase4 | Vein Occlusion | Completed | 2021-08-20 | 2022-12-08 | ClinicalTrials.gov |
| NCT04892706 | Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel an… | Phase2 | Acne Vulgaris | Completed | 2021-06-11 | 2022-09-28 | ClinicalTrials.gov |
| NCT04892706 | Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel an… | Phase2 | Acne Vulgaris | Completed | 2021-06-11 | 2022-09-28 | ClinicalTrials.gov |
| NCT04356677 | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Pa… | Phase1 | COVID19 | Withdrawn | 2021-05-01 | 2021-08-01 | ClinicalTrials.gov |
| NCT04356677 | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Pa… | Phase1 | COVID19 | Withdrawn | 2021-05-01 | 2021-08-01 | ClinicalTrials.gov |
| NCT04840563 | Surface Refractive Index Shift and Lens Absorption/Adsorption of Tear Component… | Na | Habitual Soft Contact Lens Use | Completed | 2021-04-07 | 2021-04-15 | ClinicalTrials.gov |
| NCT04840563 | Surface Refractive Index Shift and Lens Absorption/Adsorption of Tear Component… | Na | Habitual Soft Contact Lens Use | Completed | 2021-04-07 | 2021-04-15 | ClinicalTrials.gov |
| NCT04587843 | A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Re… | Phase4 | Obesity | Unknown | 2021-04-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04354545 | Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medi… | — | Glaucoma | Recruiting | 2021-04-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT04587843 | A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Re… | Phase4 | Obesity | Unknown | 2021-04-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04354545 | Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medi… | — | Glaucoma | Recruiting | 2021-04-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT03988439 | A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants… | Phase4 | Psoriasis | Completed | 2021-03-24 | 2026-02-06 | ClinicalTrials.gov |
| NCT03988439 | A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants… | Phase4 | Psoriasis | Completed | 2021-03-24 | 2026-02-06 | ClinicalTrials.gov |
| NCT05229510 | Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via… | Phase1 | Healthy | Completed | 2021-03-12 | 2021-07-12 | ClinicalTrials.gov |
| NCT05229510 | Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via… | Phase1 | Healthy | Completed | 2021-03-12 | 2021-07-12 | ClinicalTrials.gov |
| NCT04698174 | Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatm… | Na | Ametropia | Completed | 2021-02-02 | 2022-03-21 | ClinicalTrials.gov |
| NCT04698174 | Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatm… | Na | Ametropia | Completed | 2021-02-02 | 2022-03-21 | ClinicalTrials.gov |
| NCT04589130 | Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, Afte… | Phase4 | Obesity | Unknown | 2021-02-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04589130 | Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, Afte… | Phase4 | Obesity | Unknown | 2021-02-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04720105 | Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palm… | Phase4 | Palmoplantar Psoriasis | Completed | 2020-11-19 | 2022-03-29 | ClinicalTrials.gov |
| NCT04720105 | Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palm… | Phase4 | Palmoplantar Psoriasis | Completed | 2020-11-19 | 2022-03-29 | ClinicalTrials.gov |
| NCT04567329 | Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibom… | Phase3 | Dry Eye Disease | Completed | 2020-11-18 | 2021-08-30 | ClinicalTrials.gov |
| NCT04567329 | Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibom… | Phase3 | Dry Eye Disease | Completed | 2020-11-18 | 2021-08-30 | ClinicalTrials.gov |
| NCT04606368 | Bausch Health Thermage FXL for Use on Lower Face and Submentum Area | Na | Skin Wrinkling | Completed | 2020-09-29 | 2021-04-02 | ClinicalTrials.gov |
| NCT04606368 | Bausch Health Thermage FXL for Use on Lower Face and Submentum Area | Na | Skin Wrinkling | Completed | 2020-09-29 | 2021-04-02 | ClinicalTrials.gov |
| NCT04140227 | Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects W… | Phase3 | Dry Eye Disease (DED) | Completed | 2020-09-24 | 2022-01-05 | ClinicalTrials.gov |
| NCT04529811 | Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifax… | Phase1 | Healthy Volunteers | Completed | 2020-09-24 | 2021-05-09 | ClinicalTrials.gov |
| NCT04140227 | Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects W… | Phase3 | Dry Eye Disease (DED) | Completed | 2020-09-24 | 2022-01-05 | ClinicalTrials.gov |
| NCT04529811 | Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifax… | Phase1 | Healthy Volunteers | Completed | 2020-09-24 | 2021-05-09 | ClinicalTrials.gov |
| NCT04555031 | Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to… | Na | Habitual Soft Contact Lens Use | Completed | 2020-09-09 | 2020-09-16 | ClinicalTrials.gov |
| NCT04555031 | Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to… | Na | Habitual Soft Contact Lens Use | Completed | 2020-09-09 | 2020-09-16 | ClinicalTrials.gov |
| NCT05739656 | Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET | — | Astigmatism | Completed | 2020-08-01 | 2022-07-06 | ClinicalTrials.gov |
| NCT05739656 | Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET | — | Astigmatism | Completed | 2020-08-01 | 2022-07-06 | ClinicalTrials.gov |
| NCT04139798 | Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye… | Phase3 | Dry Eye Disease (DED) | Completed | 2020-07-20 | 2021-03-12 | ClinicalTrials.gov |
| NCT04139798 | Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye… | Phase3 | Dry Eye Disease (DED) | Completed | 2020-07-20 | 2021-03-12 | ClinicalTrials.gov |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lympho… | Na | Mycosis Fungoides | Withdrawn | 2020-04-01 | 2023-04-01 | ClinicalTrials.gov |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lympho… | Na | Mycosis Fungoides | Withdrawn | 2020-04-01 | 2023-04-01 | ClinicalTrials.gov |
| NCT04214652 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatmen… | Phase3 | Acne Vulgaris | Completed | 2020-01-27 | 2021-03-18 | ClinicalTrials.gov |
| NCT04214652 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatmen… | Phase3 | Acne Vulgaris | Completed | 2020-01-27 | 2021-03-18 | ClinicalTrials.gov |
| NCT03240809 | An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmaco… | Phase4 | Psoriasis | Active_Not_Recruiting | 2020-01-24 | 2029-06-01 | ClinicalTrials.gov |
| NCT03240809 | An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmaco… | Phase4 | Psoriasis | Active_Not_Recruiting | 2020-01-24 | 2029-06-01 | ClinicalTrials.gov |
| NCT04214639 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatmen… | Phase3 | Acne Vulgaris | Completed | 2020-01-17 | 2021-01-18 | ClinicalTrials.gov |
| NCT04214639 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatmen… | Phase3 | Acne Vulgaris | Completed | 2020-01-17 | 2021-01-18 | ClinicalTrials.gov |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancre… | Phase2 | Pancreatic Cancer | Withdrawn | 2020-01-06 | 2023-10-15 | ClinicalTrials.gov |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancre… | Phase2 | Pancreatic Cancer | Withdrawn | 2020-01-06 | 2023-10-15 | ClinicalTrials.gov |
| NCT04192630 | A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50 | Na | Cataract | Completed | 2019-11-26 | 2022-01-31 | ClinicalTrials.gov |
| NCT04192630 | A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50 | Na | Cataract | Completed | 2019-11-26 | 2022-01-31 | ClinicalTrials.gov |
| NCT04149899 | Safety and IOP-Lowering Effects of WB007 | Phase1 | Glaucoma, Primary Open Angle | Completed | 2019-11-14 | 2022-12-14 | ClinicalTrials.gov |
| NCT04149899 | Safety and IOP-Lowering Effects of WB007 | Phase1 | Glaucoma, Primary Open Angle | Completed | 2019-11-14 | 2022-12-14 | ClinicalTrials.gov |
| NCT04175340 | A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop | Na | Contact Lens Wear | Completed | 2019-11-07 | 2020-02-17 | ClinicalTrials.gov |
| NCT04175340 | A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop | Na | Contact Lens Wear | Completed | 2019-11-07 | 2020-02-17 | ClinicalTrials.gov |
| NCT03987763 | A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants… | Phase4 | Psoriasis | Recruiting | 2019-10-22 | 2026-06-01 | ClinicalTrials.gov |
| NCT03987763 | A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants… | Phase4 | Psoriasis | Recruiting | 2019-10-22 | 2026-06-01 | ClinicalTrials.gov |
| NCT04155801 | A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participa… | Na | Functional Gastrointestinal Disorders | Completed | 2019-10-11 | 2020-02-14 | ClinicalTrials.gov |
| NCT04155801 | A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participa… | Na | Functional Gastrointestinal Disorders | Completed | 2019-10-11 | 2020-02-14 | ClinicalTrials.gov |
| NCT04149587 | A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Respon… | — | Psoriasis | Completed | 2019-09-30 | 2022-03-30 | ClinicalTrials.gov |
| NCT04149587 | A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Respon… | — | Psoriasis | Completed | 2019-09-30 | 2022-03-30 | ClinicalTrials.gov |
| NCT04096742 | Altreno for Chest Rejuvenation | Phase4 | Photodamaged Skin | Unknown | 2019-08-06 | 2021-12-31 | ClinicalTrials.gov |
| NCT04096742 | Altreno for Chest Rejuvenation | Phase4 | Photodamaged Skin | Unknown | 2019-08-06 | 2021-12-31 | ClinicalTrials.gov |
| NCT04901897 | Product Performance of a New Silicone Hydrogel Contact Lens | Na | Myopia | Completed | 2019-07-31 | 2019-10-09 | ClinicalTrials.gov |
| NCT04901897 | Product Performance of a New Silicone Hydrogel Contact Lens | Na | Myopia | Completed | 2019-07-31 | 2019-10-09 | ClinicalTrials.gov |
| NCT04111757 | A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants W… | Na | Myopia | Completed | 2019-07-25 | 2021-08-06 | ClinicalTrials.gov |
| NCT04111757 | A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants W… | Na | Myopia | Completed | 2019-07-25 | 2021-08-06 | ClinicalTrials.gov |
| NCT04158466 | A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Co… | Na | Contact Lens Wear | Completed | 2019-05-31 | 2019-11-12 | ClinicalTrials.gov |
| NCT04158466 | A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Co… | Na | Contact Lens Wear | Completed | 2019-05-31 | 2019-11-12 | ClinicalTrials.gov |
| NCT03762915 | Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1… | Phase4 | SRP | Completed | 2019-05-20 | 2022-04-01 | ClinicalTrials.gov |
| NCT03762915 | Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1… | Phase4 | SRP | Completed | 2019-05-20 | 2022-04-01 | ClinicalTrials.gov |
| NCT03894371 | Thermage FLX System to Treat the Face, Neck, and Eyelids | Na | Facial Skin Laxity | Unknown | 2019-04-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT03894371 | Thermage FLX System to Treat the Face, Neck, and Eyelids | Na | Facial Skin Laxity | Unknown | 2019-04-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT03897751 | A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by … | Na | Contact Lens Wear | Completed | 2019-03-08 | 2019-08-01 | ClinicalTrials.gov |
| NCT03897751 | A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by … | Na | Contact Lens Wear | Completed | 2019-03-08 | 2019-08-01 | ClinicalTrials.gov |
| NCT03664739 | Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel … | Phase3 | Acne Vulgaris | Completed | 2018-12-05 | 2020-03-23 | ClinicalTrials.gov |
| NCT03664739 | Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel … | Phase3 | Acne Vulgaris | Completed | 2018-12-05 | 2020-03-23 | ClinicalTrials.gov |
| NCT03931317 | Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Bloo… | Na | OAG - Open-Angle Glaucoma | Completed | 2018-12-03 | 2023-03-01 | ClinicalTrials.gov |
| NCT03931317 | Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Bloo… | Na | OAG - Open-Angle Glaucoma | Completed | 2018-12-03 | 2023-03-01 | ClinicalTrials.gov |
| NCT03681808 | Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism | Na | Astigmatism | Completed | 2018-10-10 | 2019-12-16 | ClinicalTrials.gov |
| NCT03681808 | Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism | Na | Astigmatism | Completed | 2018-10-10 | 2019-12-16 | ClinicalTrials.gov |
| NCT03515044 | Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatme… | Phase2 | Overt Hepatic Encephalopathy | Completed | 2018-09-13 | 2020-03-12 | ClinicalTrials.gov |
| NCT03515044 | Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatme… | Phase2 | Overt Hepatic Encephalopathy | Completed | 2018-09-13 | 2020-03-12 | ClinicalTrials.gov |
| NCT03058783 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe A… | Phase3 | Atopic Dermatitis | Completed | 2018-08-14 | 2020-05-12 | ClinicalTrials.gov |
| NCT03058783 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe A… | Phase3 | Atopic Dermatitis | Completed | 2018-08-14 | 2020-05-12 | ClinicalTrials.gov |
| NCT03002571 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe A… | Phase3 | Atopic Dermatitis | Completed | 2018-07-24 | 2020-04-14 | ClinicalTrials.gov |
| NCT03002571 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe A… | Phase3 | Atopic Dermatitis | Completed | 2018-07-24 | 2020-04-14 | ClinicalTrials.gov |
| NCT03462966 | Rifaximin on Visceral Hypersensitivity | Phase2 | Visceral Hypersensitivity | Terminated | 2018-07-01 | 2021-11-19 | ClinicalTrials.gov |
| NCT03462966 | Rifaximin on Visceral Hypersensitivity | Phase2 | Visceral Hypersensitivity | Terminated | 2018-07-01 | 2021-11-19 | ClinicalTrials.gov |
| NCT03596905 | Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bo… | Phase2 | Irritable Bowel Syndrome With Constipation | Completed | 2018-06-30 | 2024-11-25 | ClinicalTrials.gov |
| NCT03596905 | Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bo… | Phase2 | Irritable Bowel Syndrome With Constipation | Completed | 2018-06-30 | 2024-11-25 | ClinicalTrials.gov |
| NCT03551873 | A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated … | — | Chronic Idiopathic Constipation | Completed | 2018-06-21 | 2018-12-14 | ClinicalTrials.gov |
| NCT03551873 | A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated … | — | Chronic Idiopathic Constipation | Completed | 2018-06-21 | 2018-12-14 | ClinicalTrials.gov |
| NCT03603600 | Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acr… | Na | Cataract | Completed | 2018-05-31 | 2023-05-04 | ClinicalTrials.gov |
| NCT03603600 | Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acr… | Na | Cataract | Completed | 2018-05-31 | 2023-05-04 | ClinicalTrials.gov |
| NCT03489941 | A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zadit… | Phase3 | Allergic Conjunctivitis | Completed | 2018-04-07 | 2018-04-29 | ClinicalTrials.gov |
| NCT03489941 | A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zadit… | Phase3 | Allergic Conjunctivitis | Completed | 2018-04-07 | 2018-04-29 | ClinicalTrials.gov |
| NCT03896633 | Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt | Phase1 | Glaucoma | Completed | 2018-02-28 | 2018-11-17 | ClinicalTrials.gov |
| NCT03896633 | Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt | Phase1 | Glaucoma | Completed | 2018-02-28 | 2018-11-17 | ClinicalTrials.gov |
| NCT03368404 | A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi … | Na | Dry Eye | Completed | 2017-11-09 | 2020-06-02 | ClinicalTrials.gov |
| NCT03368404 | A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi … | Na | Dry Eye | Completed | 2017-11-09 | 2020-06-02 | ClinicalTrials.gov |
| NCT03351101 | Clinical Study of Approved Contact Lenses | Na | Myopia | Completed | 2017-10-23 | 2017-12-08 | ClinicalTrials.gov |
| NCT03351101 | Clinical Study of Approved Contact Lenses | Na | Myopia | Completed | 2017-10-23 | 2017-12-08 | ClinicalTrials.gov |
| NCT03633851 | Toric IOL vs Non-toric IOL With LRI for Corneal Astigmatism | Na | Corneal Astigmatism | Unknown | 2017-10-03 | 2019-08-01 | ClinicalTrials.gov |
| NCT03633851 | Toric IOL vs Non-toric IOL With LRI for Corneal Astigmatism | Na | Corneal Astigmatism | Unknown | 2017-10-03 | 2019-08-01 | ClinicalTrials.gov |
| NCT03254667 | LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Pso… | — | Psoriasis | Enrolling_By_Invitation | 2017-07-25 | 2031-11-01 | ClinicalTrials.gov |
| NCT03254667 | LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Pso… | — | Psoriasis | Enrolling_By_Invitation | 2017-07-25 | 2031-11-01 | ClinicalTrials.gov |
| NCT03145025 | Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide … | — | Uveitis, Posterior | Completed | 2017-07-14 | 2019-03-22 | ClinicalTrials.gov |
| NCT03145025 | Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide … | — | Uveitis, Posterior | Completed | 2017-07-14 | 2019-03-22 | ClinicalTrials.gov |
| NCT03168334 | A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in th… | Phase3 | Acne Vulgaris | Completed | 2017-07-11 | 2018-07-24 | ClinicalTrials.gov |
| NCT03168334 | A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in th… | Phase3 | Acne Vulgaris | Completed | 2017-07-11 | 2018-07-24 | ClinicalTrials.gov |
| NCT03168321 | A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in th… | Phase3 | Acne Vulgaris | Completed | 2017-06-29 | 2018-06-07 | ClinicalTrials.gov |
| NCT03168321 | A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in th… | Phase3 | Acne Vulgaris | Completed | 2017-06-29 | 2018-06-07 | ClinicalTrials.gov |
| NCT03249233 | Corneal Thickness Changes With Scleral Contact Lenses | Na | Keratoconus | Unknown | 2017-06-22 | 2020-12-01 | ClinicalTrials.gov |
| NCT03249233 | Corneal Thickness Changes With Scleral Contact Lenses | Na | Keratoconus | Unknown | 2017-06-22 | 2020-12-01 | ClinicalTrials.gov |
| NCT03327558 | Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in… | Phase1 | Ulcerative Colitis | Completed | 2017-05-15 | 2017-08-18 | ClinicalTrials.gov |
| NCT03327558 | Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in… | Phase1 | Ulcerative Colitis | Completed | 2017-05-15 | 2017-08-18 | ClinicalTrials.gov |
| NCT03098953 | Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single… | Phase1 | Healthy | Completed | 2017-04-10 | 2017-05-12 | ClinicalTrials.gov |
| NCT03098953 | Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single… | Phase1 | Healthy | Completed | 2017-04-10 | 2017-05-12 | ClinicalTrials.gov |
| NCT03282929 | Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in He… | Phase1 | Anaphylaxis | Completed | 2017-03-23 | 2018-10-15 | ClinicalTrials.gov |
| NCT03282929 | Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in He… | Phase1 | Anaphylaxis | Completed | 2017-03-23 | 2018-10-15 | ClinicalTrials.gov |
| NCT03544216 | Accommodative Relief for Uncomfortable Non-Presbyopes | Na | Asthenopia | Completed | 2017-02-02 | 2018-05-06 | ClinicalTrials.gov |
| NCT03544216 | Accommodative Relief for Uncomfortable Non-Presbyopes | Na | Asthenopia | Completed | 2017-02-02 | 2018-05-06 | ClinicalTrials.gov |
| NCT03122457 | Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide | Phase2 | Actinic Keratosis | Completed | 2017-01-01 | 2018-07-19 | ClinicalTrials.gov |
| NCT03120520 | An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of A… | Phase2 | Chronic Idiopathic Constipation | Completed | 2017-01-01 | 2018-09-07 | ClinicalTrials.gov |
| NCT03120520 | An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of A… | Phase2 | Chronic Idiopathic Constipation | Completed | 2017-01-01 | 2018-09-07 | ClinicalTrials.gov |
| NCT03122457 | Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide | Phase2 | Actinic Keratosis | Completed | 2017-01-01 | 2018-07-19 | ClinicalTrials.gov |
| NCT01951209 | Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis | Na | Liver Cirrhosis | Terminated | 2016-11-17 | 2017-06-12 | ClinicalTrials.gov |
| NCT01951209 | Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis | Na | Liver Cirrhosis | Terminated | 2016-11-17 | 2017-06-12 | ClinicalTrials.gov |
| NCT02812771 | Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With … | Phase4 | Onychomycosis | Completed | 2016-08-04 | 2019-01-14 | ClinicalTrials.gov |
| NCT02812771 | Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With … | Phase4 | Onychomycosis | Completed | 2016-08-04 | 2019-01-14 | ClinicalTrials.gov |
| NCT02849873 | Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With… | Phase1 | Acne | Completed | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02850003 | Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel | Phase1 | Acne | Completed | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02785185 | Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With M… | Phase2 | Psoriasis | Completed | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02786901 | LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Sur… | Phase3 | Cataract | Completed | 2016-06-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02785185 | Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With M… | Phase2 | Psoriasis | Completed | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02786901 | LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Sur… | Phase3 | Cataract | Completed | 2016-06-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02850003 | Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel | Phase1 | Acne | Completed | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02849873 | Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With… | Phase1 | Acne | Completed | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02785172 | Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque … | Phase2 | Psoriasis | Completed | 2016-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02785172 | Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque … | Phase2 | Psoriasis | Completed | 2016-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02767947 | Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Parti… | Phase4 | Tinea Corporis | Completed | 2016-02-08 | 2016-09-22 | ClinicalTrials.gov |
| NCT02767947 | Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Parti… | Phase4 | Tinea Corporis | Completed | 2016-02-08 | 2016-09-22 | ClinicalTrials.gov |
| NCT02785159 | Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis | Phase2 | Psoriasis | Completed | 2016-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02785159 | Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis | Phase2 | Psoriasis | Completed | 2016-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02682680 | Randomized Trial Comparing Colesevelam vs. Ezetimibe | Phase4 | Type 2 Diabetes Mellitus | Completed | 2016-01-11 | 2017-05-25 | ClinicalTrials.gov |
| NCT02682680 | Randomized Trial Comparing Colesevelam vs. Ezetimibe | Phase4 | Type 2 Diabetes Mellitus | Completed | 2016-01-11 | 2017-05-25 | ClinicalTrials.gov |
| NCT02457026 | Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in … | Na | Neovascular Age-related Macular Degeneration | Withdrawn | 2016-01-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02706483 | Long Term Safety Study of Plecanatide | Phase3 | Irritable Bowel Syndrome | Completed | 2016-01-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02706483 | Long Term Safety Study of Plecanatide | Phase3 | Irritable Bowel Syndrome | Completed | 2016-01-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02457026 | Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in … | Na | Neovascular Age-related Macular Degeneration | Withdrawn | 2016-01-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02767271 | Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to… | Phase4 | Tinea Pedis | Completed | 2015-12-02 | 2016-04-27 | ClinicalTrials.gov |
| NCT02767271 | Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to… | Phase4 | Tinea Pedis | Completed | 2015-12-02 | 2016-04-27 | ClinicalTrials.gov |
| NCT02965456 | Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of A… | Phase3 | Acne | Completed | 2015-11-04 | 2017-02-23 | ClinicalTrials.gov |
| NCT02965456 | Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of A… | Phase3 | Acne | Completed | 2015-11-04 | 2017-02-23 | ClinicalTrials.gov |
| NCT03003247 | Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris | Phase2 | Acne Vulgaris | Completed | 2015-11-01 | 2016-09-30 | ClinicalTrials.gov |
| NCT03003247 | Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris | Phase2 | Acne Vulgaris | Completed | 2015-11-01 | 2016-09-30 | ClinicalTrials.gov |
| NCT02938494 | Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Ac… | Phase2 | Acne Vulgaris | Completed | 2015-11-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02938494 | Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Ac… | Phase2 | Acne Vulgaris | Completed | 2015-11-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02462122 | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2015-08-19 | 2016-11-14 | ClinicalTrials.gov |
| NCT02462122 | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2015-08-19 | 2016-11-14 | ClinicalTrials.gov |
| NCT02462083 | Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2015-08-11 | 2017-04-24 | ClinicalTrials.gov |
| NCT02462083 | Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2015-08-11 | 2017-04-24 | ClinicalTrials.gov |
| NCT02493452 | Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2015-06-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02493452 | Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2015-06-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02452840 | Photodynamic Therapy for PDA in NV AMD | — | Neovascular Age-related Macular Degeneration | Completed | 2015-05-11 | 2019-08-01 | ClinicalTrials.gov |
| NCT02452840 | Photodynamic Therapy for PDA in NV AMD | — | Neovascular Age-related Macular Degeneration | Completed | 2015-05-11 | 2019-08-01 | ClinicalTrials.gov |
| NCT02508805 | Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy | Phase3 | Vertebrogenic Radiculopathy L5, S1 | Completed | 2015-05-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02508805 | Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy | Phase3 | Vertebrogenic Radiculopathy L5, S1 | Completed | 2015-05-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02939950 | Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis | Na | Myopia | Completed | 2015-04-30 | 2016-08-03 | ClinicalTrials.gov |
| NCT02939950 | Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis | Na | Myopia | Completed | 2015-04-30 | 2016-08-03 | ClinicalTrials.gov |
| NCT03058744 | Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate … | Phase1 | Psoriasis | Completed | 2015-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT03058744 | Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate … | Phase1 | Psoriasis | Completed | 2015-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02394379 | Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL | — | Cataract | Completed | 2015-03-19 | 2019-08-05 | ClinicalTrials.gov |
| NCT02394379 | Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL | — | Cataract | Completed | 2015-03-19 | 2019-08-05 | ClinicalTrials.gov |
| NCT02394340 | Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Par… | Phase4 | Tinea Pedis | Completed | 2015-02-03 | 2015-04-01 | ClinicalTrials.gov |
| NCT02394340 | Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Par… | Phase4 | Tinea Pedis | Completed | 2015-02-03 | 2015-04-01 | ClinicalTrials.gov |
| NCT02307864 | Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarizati… | Phase1 | Healthy | Completed | 2014-12-04 | 2015-08-27 | ClinicalTrials.gov |
| NCT02307864 | Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarizati… | Phase1 | Healthy | Completed | 2014-12-04 | 2015-08-27 | ClinicalTrials.gov |
| NCT02387359 | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2014-12-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02299206 | CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants | Na | Diaper Rash | Terminated | 2014-12-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02299206 | CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants | Na | Diaper Rash | Terminated | 2014-12-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02387359 | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2014-12-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02258139 | Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Le… | Na | Corneal Deformity | Completed | 2014-11-03 | 2014-12-11 | ClinicalTrials.gov |
| NCT02258139 | Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Le… | Na | Corneal Deformity | Completed | 2014-11-03 | 2014-12-11 | ClinicalTrials.gov |
| NCT02240108 | One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2014-10-28 | 2017-10-06 | ClinicalTrials.gov |
| NCT02240108 | One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2014-10-28 | 2017-10-06 | ClinicalTrials.gov |
| NCT02173392 | A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Dose… | Phase1 | Psoriasis | Completed | 2014-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02208297 | Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation a… | Phase3 | Inflammation | Completed | 2014-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02208297 | Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation a… | Phase3 | Inflammation | Completed | 2014-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02173392 | A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Dose… | Phase1 | Psoriasis | Completed | 2014-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02240121 | One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2014-08-21 | 2017-08-16 | ClinicalTrials.gov |
| NCT02240121 | One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2014-08-21 | 2017-08-16 | ClinicalTrials.gov |
| NCT02122471 | 12-Week Study of Plecanatide for CIC (The National CIC3 Study) | Phase3 | Chronic Idiopathic Constipation | Completed | 2014-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02122471 | 12-Week Study of Plecanatide for CIC (The National CIC3 Study) | Phase3 | Chronic Idiopathic Constipation | Completed | 2014-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02322528 | Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax | Na | Sjogren's Disease | Completed | 2014-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02322528 | Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax | Na | Sjogren's Disease | Completed | 2014-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02024646 | Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Completed | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02029495 | Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab … | Phase3 | Psoriatic Arthritis | Terminated | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02029495 | Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab … | Phase3 | Psoriatic Arthritis | Terminated | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02024646 | Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Completed | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01959243 | Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric… | Phase3 | Hyperemia | Completed | 2014-02-22 | 2014-06-23 | ClinicalTrials.gov |
| NCT01959243 | Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric… | Phase3 | Hyperemia | Completed | 2014-02-22 | 2014-06-23 | ClinicalTrials.gov |
| NCT02039765 | Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate O… | Phase1 | Hyperemia | Completed | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02039765 | Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate O… | Phase1 | Hyperemia | Completed | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02849860 | Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With A… | Phase1 | Acne | Completed | 2014-02-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02849860 | Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With A… | Phase1 | Acne | Completed | 2014-02-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02382588 | Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for th… | Phase2 | Herpes Zoster Keratitis | Terminated | 2013-12-10 | 2020-05-11 | ClinicalTrials.gov |
| NCT02382588 | Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for th… | Phase2 | Herpes Zoster Keratitis | Terminated | 2013-12-10 | 2020-05-11 | ClinicalTrials.gov |
| NCT02047604 | (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients Wit… | Phase2 | Rheumatoid Arthritis | Completed | 2013-12-01 | 2017-03-23 | ClinicalTrials.gov |
| NCT02024711 | EYEFILL® C. -US Viscoelastic Clinical Investigation | Na | Cataract | Completed | 2013-12-01 | 2014-12-17 | ClinicalTrials.gov |
| NCT01996839 | Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Fo… | Phase3 | Inflammation | Completed | 2013-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02047604 | (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients Wit… | Phase2 | Rheumatoid Arthritis | Completed | 2013-12-01 | 2017-03-23 | ClinicalTrials.gov |
| NCT02024711 | EYEFILL® C. -US Viscoelastic Clinical Investigation | Na | Cataract | Completed | 2013-12-01 | 2014-12-17 | ClinicalTrials.gov |
| NCT01996839 | Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Fo… | Phase3 | Inflammation | Completed | 2013-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01959230 | Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Ge… | Phase3 | Hyperemia | Completed | 2013-11-07 | 2013-12-20 | ClinicalTrials.gov |
| NCT01959230 | Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Ge… | Phase3 | Hyperemia | Completed | 2013-11-07 | 2013-12-20 | ClinicalTrials.gov |
| NCT01983306 | Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of… | Phase2 | Constipation | Completed | 2013-11-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01983306 | Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of… | Phase2 | Constipation | Completed | 2013-11-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01982240 | 12-Week Study of Plecanatide for CIC (The CIC3 Study) | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01982240 | 12-Week Study of Plecanatide for CIC (The CIC3 Study) | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT03886779 | Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07… | Phase4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | Completed | 2013-10-30 | 2019-03-01 | ClinicalTrials.gov |
| NCT03886779 | Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07… | Phase4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | Completed | 2013-10-30 | 2019-03-01 | ClinicalTrials.gov |
| NCT01562132 | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment o… | Phase2 | Cryptococcal Infection Disseminated | Terminated | 2013-09-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01562132 | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment o… | Phase2 | Cryptococcal Infection Disseminated | Terminated | 2013-09-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01919697 | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipa… | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01947920 | A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-08-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01947920 | A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-08-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01919697 | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipa… | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01895985 | Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese H… | Phase1 | Intraocular Pressure | Completed | 2013-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01895985 | Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese H… | Phase1 | Intraocular Pressure | Completed | 2013-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01928693 | A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infe… | Phase2 | Corneal Ulcers | Terminated | 2013-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01928693 | A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infe… | Phase2 | Corneal Ulcers | Terminated | 2013-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01475643 | Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Follo… | Phase3 | Cataract | Completed | 2013-06-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01475643 | Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Follo… | Phase3 | Cataract | Completed | 2013-06-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01959178 | A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens | Na | Presbyopia | Completed | 2013-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01959178 | A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens | Na | Presbyopia | Completed | 2013-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01817582 | Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Kera… | Phase2 | Keratoconjunctivitis Sicca | Completed | 2013-05-17 | 2014-01-10 | ClinicalTrials.gov |
| NCT01817582 | Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Kera… | Phase2 | Keratoconjunctivitis Sicca | Completed | 2013-05-17 | 2014-01-10 | ClinicalTrials.gov |
| NCT01791426 | A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vis… | Na | Dry Eye | Withdrawn | 2013-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01791426 | A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vis… | Na | Dry Eye | Withdrawn | 2013-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01846663 | Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hep… | Phase4 | Hepatic Encephalopathy | Terminated | 2013-04-03 | 2016-02-22 | ClinicalTrials.gov |
| NCT01846663 | Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hep… | Phase4 | Hepatic Encephalopathy | Terminated | 2013-04-03 | 2016-02-22 | ClinicalTrials.gov |
| NCT01873846 | A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2013-04-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01847638 | Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of O… | Na | Cataract | Completed | 2013-04-01 | 2018-08-23 | ClinicalTrials.gov |
| NCT01847638 | Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of O… | Na | Cataract | Completed | 2013-04-01 | 2018-08-23 | ClinicalTrials.gov |
| NCT01873846 | A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2013-04-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01740388 | Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in … | Phase3 | Bacterial Conjunctivitis | Terminated | 2013-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01740388 | Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in … | Phase3 | Bacterial Conjunctivitis | Terminated | 2013-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01749904 | Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects … | Phase3 | Open-Angle Glaucoma | Completed | 2013-01-31 | 2015-09-30 | ClinicalTrials.gov |
| NCT01749904 | Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects … | Phase3 | Open-Angle Glaucoma | Completed | 2013-01-31 | 2015-09-30 | ClinicalTrials.gov |
| NCT01842581 | The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A … | Phase4 | Hepatic Encephalopathy | Completed | 2013-01-08 | 2014-12-17 | ClinicalTrials.gov |
| NCT01842581 | The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A … | Phase4 | Hepatic Encephalopathy | Completed | 2013-01-08 | 2014-12-17 | ClinicalTrials.gov |
| NCT03914417 | Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod … | Phase2 | Actinic Keratosis | Completed | 2013-01-01 | 2015-04-30 | ClinicalTrials.gov |
| NCT03914417 | Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod … | Phase2 | Actinic Keratosis | Completed | 2013-01-01 | 2015-04-30 | ClinicalTrials.gov |
| NCT01753739 | Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhiniti… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2013-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01753739 | Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhiniti… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2013-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01707381 | BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular H… | Phase2 | Ocular Hypertension | Completed | 2012-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01707381 | BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular H… | Phase2 | Ocular Hypertension | Completed | 2012-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01701024 | Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Sev… | Phase3 | Acne | Completed | 2012-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01654939 | Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients … | Phase4 | HIV | Withdrawn | 2012-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01705938 | Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacoki… | Phase1 | Exposure | Completed | 2012-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01701024 | Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Sev… | Phase3 | Acne | Completed | 2012-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01654939 | Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients … | Phase4 | HIV | Withdrawn | 2012-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01705938 | Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacoki… | Phase1 | Exposure | Completed | 2012-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01668654 | Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatr… | Phase3 | Epilepsy | Terminated | 2012-09-04 | 2013-06-18 | ClinicalTrials.gov |
| NCT01668654 | Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatr… | Phase3 | Epilepsy | Terminated | 2012-09-04 | 2013-06-18 | ClinicalTrials.gov |
| NCT01846806 | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Ence… | Na | Hepatic Encephalopathy | Terminated | 2012-09-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01846806 | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Ence… | Na | Hepatic Encephalopathy | Terminated | 2012-09-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01708629 | Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Mode… | Phase3 | Plaque Psoriasis | Terminated | 2012-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01708629 | Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Mode… | Phase3 | Plaque Psoriasis | Terminated | 2012-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01708590 | Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to… | Phase3 | Psoriasis | Terminated | 2012-08-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01708603 | P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis | Phase3 | Moderate to Severe Plaque Psoriasis | Terminated | 2012-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01708590 | Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to… | Phase3 | Psoriasis | Terminated | 2012-08-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01708603 | P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis | Phase3 | Moderate to Severe Plaque Psoriasis | Terminated | 2012-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01591161 | Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation a… | Phase3 | Cataract | Completed | 2012-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01591655 | Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation a… | Phase3 | Cataract | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01591161 | Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation a… | Phase3 | Cataract | Completed | 2012-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01591655 | Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation a… | Phase3 | Cataract | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01650584 | Evaluation of Ocular Comfort With ISTA Tears vs Systane | Na | Dry Eye Disease | Completed | 2012-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01650584 | Evaluation of Ocular Comfort With ISTA Tears vs Systane | Na | Dry Eye Disease | Completed | 2012-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01647906 | Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Trea… | — | Fecal Incontinence | Completed | 2012-05-31 | 2018-09-15 | ClinicalTrials.gov |
| NCT01647906 | Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Trea… | — | Fecal Incontinence | Completed | 2012-05-31 | 2018-09-15 | ClinicalTrials.gov |
| NCT01583868 | A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contac… | Na | Myopia | Completed | 2012-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01583868 | A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contac… | Na | Myopia | Completed | 2012-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01543178 | Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study | Phase3 | Irritable Bowel Syndrome With Diarrhea | Completed | 2012-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01543178 | Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study | Phase3 | Irritable Bowel Syndrome With Diarrhea | Completed | 2012-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01532648 | Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 … | Phase3 | Ulcerative Colitis | Completed | 2012-01-27 | 2013-10-02 | ClinicalTrials.gov |
| NCT01532648 | Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 … | Phase3 | Ulcerative Colitis | Completed | 2012-01-27 | 2013-10-02 | ClinicalTrials.gov |
| NCT01722604 | Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt | Phase3 | Glaucoma | Completed | 2012-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01518868 | A Study to Evaluate the Feasibility of a High Add Multi Focal Contact Lens | Na | Presbyopia | Completed | 2012-01-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01539694 | A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contac… | Na | Presbyopia | Completed | 2012-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01518868 | A Study to Evaluate the Feasibility of a High Add Multi Focal Contact Lens | Na | Presbyopia | Completed | 2012-01-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01539694 | A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contac… | Na | Presbyopia | Completed | 2012-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01533480 | A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Tr… | Phase4 | Keratoconjunctivitis Due to Adenovirus | Completed | 2012-01-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01722604 | Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt | Phase3 | Glaucoma | Completed | 2012-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01533480 | A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Tr… | Phase4 | Keratoconjunctivitis Due to Adenovirus | Completed | 2012-01-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01429987 | The Plecanatide Chronic Idiopathic Constipation (CIC) Study | Phase2 | Chronic Idiopathic Constipation | Completed | 2011-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01516957 | AMG 827 in Subjects With Psoriatic Arthritis | Phase2 | Psoriatic Arthritis | Terminated | 2011-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01429987 | The Plecanatide Chronic Idiopathic Constipation (CIC) Study | Phase2 | Chronic Idiopathic Constipation | Completed | 2011-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01516957 | AMG 827 in Subjects With Psoriatic Arthritis | Phase2 | Psoriatic Arthritis | Terminated | 2011-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01427296 | Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Table… | Phase4 | Colon Cleansing | Completed | 2011-09-16 | 2014-12-09 | ClinicalTrials.gov |
| NCT01427296 | Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Table… | Phase4 | Colon Cleansing | Completed | 2011-09-16 | 2014-12-09 | ClinicalTrials.gov |
| NCT01431170 | Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrima… | Phase1 | Congenital Nasolacrimal Duct Obstruction | Completed | 2011-09-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01431170 | Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrima… | Phase1 | Congenital Nasolacrimal Duct Obstruction | Completed | 2011-09-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01478256 | Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for… | Phase4 | Blepharitis | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01478256 | Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for… | Phase4 | Blepharitis | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01456780 | Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/… | Phase4 | Meibomian Gland Dysfunction | Completed | 2011-08-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01449526 | A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2011-08-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01449526 | A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2011-08-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01412983 | A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01695668 | Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol E… | Na | Dry Eyes | Completed | 2011-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01456780 | Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/… | Phase4 | Meibomian Gland Dysfunction | Completed | 2011-08-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01695668 | Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol E… | Na | Dry Eyes | Completed | 2011-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01412983 | A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact … | Na | Myopia | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01542541 | A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Sc… | Na | Intestinal FDG Uptake | Completed | 2011-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01542541 | A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Sc… | Na | Intestinal FDG Uptake | Completed | 2011-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01374490 | Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea | Phase3 | HIV Enteropathy | Completed | 2011-06-07 | 2012-10-31 | ClinicalTrials.gov |
| NCT01374490 | Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea | Phase3 | HIV Enteropathy | Completed | 2011-06-07 | 2012-10-31 | ClinicalTrials.gov |
| NCT01375582 | Objective Evaluation of Ocular Surface Lubricants in Two Environments | Early_Phase1 | Dry Eye | Completed | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01365039 | Safety and Efficacy of a Contact Lens for Daily Disposable Use | Na | Myopia | Completed | 2011-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01375582 | Objective Evaluation of Ocular Surface Lubricants in Two Environments | Early_Phase1 | Dry Eye | Completed | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01365039 | Safety and Efficacy of a Contact Lens for Daily Disposable Use | Na | Myopia | Completed | 2011-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01367249 | Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surge… | Phase3 | Pain | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01330355 | Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in N… | Phase3 | Bacterial Conjunctivitis | Terminated | 2011-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01367249 | Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surge… | Phase3 | Pain | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01330355 | Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in N… | Phase3 | Bacterial Conjunctivitis | Terminated | 2011-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01416272 | Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses | Na | Keratoconus | Terminated | 2011-04-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01416272 | Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses | Na | Keratoconus | Terminated | 2011-04-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01339507 | A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft | — | Allergic Conjunctivitis | Completed | 2011-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01339507 | A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft | — | Allergic Conjunctivitis | Completed | 2011-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01326780 | A Study of a New Drug Treatment for Acne | Phase2 | Acne Vulgaris | Completed | 2011-03-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT01326780 | A Study of a New Drug Treatment for Acne | Phase2 | Acne Vulgaris | Completed | 2011-03-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT01133353 | A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjec… | Phase2 | Tourette's Syndrome | Withdrawn | 2011-03-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01133353 | A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjec… | Phase2 | Tourette's Syndrome | Withdrawn | 2011-03-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01317030 | Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wear… | — | Dry Eye | Terminated | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01289431 | Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis | Phase2 | Conjunctivitis, Allergic | Completed | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01317030 | Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wear… | — | Dry Eye | Terminated | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01289431 | Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis | Phase2 | Conjunctivitis, Allergic | Completed | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01223378 | Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subje… | Phase2 | Intraocular Pressure | Completed | 2010-12-13 | 2012-06-22 | ClinicalTrials.gov |
| NCT01223378 | Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subje… | Phase2 | Intraocular Pressure | Completed | 2010-12-13 | 2012-06-22 | ClinicalTrials.gov |
| NCT01309867 | A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses | Na | Myopia | Completed | 2010-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01313728 | A Study That Evaluates the Decrease in Irritation When Using Additional Acne Tr… | Phase4 | Acne Vulgaris | Completed | 2010-12-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01277341 | Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Sea… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2010-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01277341 | Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Sea… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2010-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01309867 | A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses | Na | Myopia | Completed | 2010-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01313728 | A Study That Evaluates the Decrease in Irritation When Using Additional Acne Tr… | Phase4 | Acne Vulgaris | Completed | 2010-12-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01318577 | Study of A New Contact Lens Cleaning and Disinfecting Solution | Na | Vision Disorders | Completed | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01309100 | Product Feasibility of a New Silicone Hydrogel Contact Lens | Na | Myopia | Completed | 2010-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01230125 | Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Follo… | Phase3 | Cataract | Completed | 2010-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01230125 | Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Follo… | Phase3 | Cataract | Completed | 2010-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01318577 | Study of A New Contact Lens Cleaning and Disinfecting Solution | Na | Vision Disorders | Completed | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01309100 | Product Feasibility of a New Silicone Hydrogel Contact Lens | Na | Myopia | Completed | 2010-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01241279 | Accommodation Measurements After Bilateral Implantation of an Aspheric Accommod… | Phase4 | Cataract | Terminated | 2010-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01230060 | One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract … | Phase3 | Aphakia | Completed | 2010-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01241279 | Accommodation Measurements After Bilateral Implantation of an Aspheric Accommod… | Phase4 | Cataract | Terminated | 2010-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01230060 | One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract … | Phase3 | Aphakia | Completed | 2010-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01186770 | A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Con… | Phase3 | Opioid-Induced Constipation | Completed | 2010-09-01 | 2011-09-08 | ClinicalTrials.gov |
| NCT01455233 | 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cat… | Phase4 | Corneal Health | Completed | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01455233 | 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cat… | Phase4 | Corneal Health | Completed | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01186770 | A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Con… | Phase3 | Opioid-Induced Constipation | Completed | 2010-09-01 | 2011-09-08 | ClinicalTrials.gov |
| NCT01437982 | A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.… | Phase4 | Conjunctivitis, Seasonal Allergic | Completed | 2010-08-05 | 2015-10-19 | ClinicalTrials.gov |
| NCT01437982 | A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.… | Phase4 | Conjunctivitis, Seasonal Allergic | Completed | 2010-08-05 | 2015-10-19 | ClinicalTrials.gov |
| NCT01230554 | Product Performance of a Daily Disposable Contact Lens | Na | Myopia | Completed | 2010-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01230554 | Product Performance of a Daily Disposable Contact Lens | Na | Myopia | Completed | 2010-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01159015 | Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Voluntee… | Phase3 | Allergic Conjunctivitis | Completed | 2010-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01149811 | A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adu… | — | Parkinson's Disease | Completed | 2010-07-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01366326 | Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult … | Phase1 | Healthy Adult Subjects | Completed | 2010-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01159015 | Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Voluntee… | Phase3 | Allergic Conjunctivitis | Completed | 2010-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01366326 | Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult … | Phase1 | Healthy Adult Subjects | Completed | 2010-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01149811 | A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adu… | — | Parkinson's Disease | Completed | 2010-07-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01122576 | Evaluation of 3 Intraocular Lenses Following Lens Extraction | Phase4 | Cataract | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01175590 | Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehi… | Phase3 | Bacterial Conjunctivitis | Completed | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01174823 | Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal All… | Phase2 | Allergic Conjunctivitis | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01140841 | A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkins… | — | Parkinson's Disease | Completed | 2010-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01131481 | Evaluation of Glistenings in Intraocular Lenses Implanted in Normal Patients Fo… | Phase4 | Glistenings | Withdrawn | 2010-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01299779 | Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS | Na | Hyponatremia | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01140841 | A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkins… | — | Parkinson's Disease | Completed | 2010-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01299779 | Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS | Na | Hyponatremia | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01174823 | Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal All… | Phase2 | Allergic Conjunctivitis | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01090102 | Mesalamine to Reduce T Cell Activation in HIV Infection | Phase4 | HIV Infections | Completed | 2010-06-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01122576 | Evaluation of 3 Intraocular Lenses Following Lens Extraction | Phase4 | Cataract | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01090102 | Mesalamine to Reduce T Cell Activation in HIV Infection | Phase4 | HIV Infections | Completed | 2010-06-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01175590 | Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehi… | Phase3 | Bacterial Conjunctivitis | Completed | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01131481 | Evaluation of Glistenings in Intraocular Lenses Implanted in Normal Patients Fo… | Phase4 | Glistenings | Withdrawn | 2010-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01142089 | Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX)… | Phase3 | Traveler's Diarrhea | Completed | 2010-05-27 | 2012-06-01 | ClinicalTrials.gov |
| NCT01142089 | Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX)… | Phase3 | Traveler's Diarrhea | Completed | 2010-05-27 | 2012-06-01 | ClinicalTrials.gov |
| NCT01125930 | Atralin Gel for the Treatment of Rosacea | Phase3 | Rosacea | Terminated | 2010-05-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01384266 | A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Follo… | — | Intraocular Inflammation | Completed | 2010-05-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01222299 | Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product Af… | Phase1 | Seasonal Allergic Rhinitis | Completed | 2010-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01131130 | Feasibility of a New Silicone Hydrogel Lens | Na | Myopia | Completed | 2010-05-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01125930 | Atralin Gel for the Treatment of Rosacea | Phase3 | Rosacea | Terminated | 2010-05-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01118338 | Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses | Na | Myopia | Completed | 2010-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01222299 | Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product Af… | Phase1 | Seasonal Allergic Rhinitis | Completed | 2010-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01131130 | Feasibility of a New Silicone Hydrogel Lens | Na | Myopia | Completed | 2010-05-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01118338 | Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses | Na | Myopia | Completed | 2010-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01384266 | A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Follo… | — | Intraocular Inflammation | Completed | 2010-05-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01573572 | Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium | Phase4 | Age-Related Macular Degeneration | Completed | 2010-04-22 | 2019-11-14 | ClinicalTrials.gov |
| NCT01573572 | Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium | Phase4 | Age-Related Macular Degeneration | Completed | 2010-04-22 | 2019-11-14 | ClinicalTrials.gov |
| NCT01130974 | A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens | Na | Myopia | Completed | 2010-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01130974 | A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens | Na | Myopia | Completed | 2010-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01107405 | Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Pl… | Phase2 | Allergic Conjunctivitis | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01101100 | Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in … | Phase2 | Psoriasis | Terminated | 2010-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01101100 | Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in … | Phase2 | Psoriasis | Terminated | 2010-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01107405 | Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Pl… | Phase2 | Allergic Conjunctivitis | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01053962 | SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation | Phase2 | Chronic Idiopathic Constipation | Completed | 2010-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01053962 | SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation | Phase2 | Chronic Idiopathic Constipation | Completed | 2010-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01069133 | Study of Rifaximin in Minimal Hepatic Encephalopathy | Phase1 | Minimal Hepatic Encephalopathy | Completed | 2010-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01100112 | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Ta… | Phase3 | Colitis, Ulcerative | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01069133 | Study of Rifaximin in Minimal Hepatic Encephalopathy | Phase1 | Minimal Hepatic Encephalopathy | Completed | 2010-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00770133 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challeng… | Phase3 | Allergic Conjunctivitis | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00770133 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challeng… | Phase3 | Allergic Conjunctivitis | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01100112 | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Ta… | Phase3 | Colitis, Ulcerative | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Ref… | Phase4 | Refractory Cutaneous T-cell Lymphoma | Completed | 2010-01-06 | 2014-02-20 | ClinicalTrials.gov |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Ref… | Phase4 | Refractory Cutaneous T-cell Lymphoma | Completed | 2010-01-06 | 2014-02-20 | ClinicalTrials.gov |
| NCT01472874 | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease | Na | Wilson Disease | Completed | 2010-01-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01472874 | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease | Na | Wilson Disease | Completed | 2010-01-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00975637 | Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects… | Phase2 | Psoriasis | Completed | 2009-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00975637 | Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects… | Phase2 | Psoriasis | Completed | 2009-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01008423 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Mod… | Phase3 | Proctitis | Completed | 2009-11-20 | 2013-03-18 | ClinicalTrials.gov |
| NCT01008423 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Mod… | Phase3 | Proctitis | Completed | 2009-11-20 | 2013-03-18 | ClinicalTrials.gov |
| NCT01010633 | Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain… | Phase3 | Inflammation | Completed | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01024751 | A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution | Na | Ocular Discomfort | Completed | 2009-11-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01010633 | Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain… | Phase3 | Inflammation | Completed | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01024751 | A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution | Na | Ocular Discomfort | Completed | 2009-11-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01028027 | Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatmen… | Phase3 | Conjunctivitis | Completed | 2009-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00983736 | Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculati… | Phase3 | Premature Ejaculation | Terminated | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00972777 | Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Co… | Phase2 | Bacterial Conjunctivitis | Completed | 2009-10-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00972777 | Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Co… | Phase2 | Bacterial Conjunctivitis | Completed | 2009-10-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00983736 | Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculati… | Phase3 | Premature Ejaculation | Terminated | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01028027 | Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatmen… | Phase3 | Conjunctivitis | Completed | 2009-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00992693 | Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Tr… | Phase2 | Crimean-Congo Hemorrhagic Fever | Withdrawn | 2009-09-01 | 2019-12-17 | ClinicalTrials.gov |
| NCT00992693 | Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Tr… | Phase2 | Crimean-Congo Hemorrhagic Fever | Withdrawn | 2009-09-01 | 2019-12-17 | ClinicalTrials.gov |
| NCT00985231 | Performance Evaluation of Contact Lenses Among a Population of Adapted Contact … | Na | Vision Disorders | Completed | 2009-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00985231 | Performance Evaluation of Contact Lenses Among a Population of Adapted Contact … | Na | Vision Disorders | Completed | 2009-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00983151 | Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculat… | Phase3 | Premature Ejaculation | Terminated | 2009-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00945334 | Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation … | Na | Constipation-predominant Irritable Bowel Syndrome | Completed | 2009-08-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00983151 | Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculat… | Phase3 | Premature Ejaculation | Terminated | 2009-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00945334 | Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation … | Na | Constipation-predominant Irritable Bowel Syndrome | Completed | 2009-08-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00936884 | Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-… | Phase3 | Constipation | Completed | 2009-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00936884 | Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-… | Phase3 | Constipation | Completed | 2009-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00952523 | Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Ap… | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00952523 | Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Ap… | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00905450 | Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Fol… | Phase2 | Cataract | Completed | 2009-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00905450 | Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Fol… | Phase2 | Cataract | Completed | 2009-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00919191 | Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Fa… | Phase4 | Acne Vulgaris | Completed | 2009-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00919191 | Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Fa… | Phase4 | Acne Vulgaris | Completed | 2009-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00858754 | Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-I… | Phase4 | Opioid-Induced Constipation | Withdrawn | 2009-03-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00905762 | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunct… | Phase1 | Healthy | Completed | 2009-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00858754 | Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-I… | Phase4 | Opioid-Induced Constipation | Withdrawn | 2009-03-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00869687 | Biopsy Study for Sculptra (Poly-L-Lactic Acid) | Na | Healthy Volunteers | Completed | 2009-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00869687 | Biopsy Study for Sculptra (Poly-L-Lactic Acid) | Na | Healthy Volunteers | Completed | 2009-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00905762 | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunct… | Phase1 | Healthy | Completed | 2009-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00907257 | A Study of Different Use Regimens Using Two Acne Treatments | Phase4 | Acne Vulgaris | Completed | 2009-02-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00824070 | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin… | Phase1 | Cataract Extraction | Completed | 2009-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00825513 | Safety and Effectiveness of the Akreos Toric Intraocular Lens. | Phase4 | Cataract | Completed | 2009-02-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00824070 | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin… | Phase1 | Cataract Extraction | Completed | 2009-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00825513 | Safety and Effectiveness of the Akreos Toric Intraocular Lens. | Phase4 | Cataract | Completed | 2009-02-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00853970 | Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract… | Phase3 | Pain | Completed | 2009-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00854061 | Study of T-PRED(TM) Compared to Pred Forte(R) II | Phase3 | Cataract | Completed | 2009-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00907335 | A Study of Acne Treatment in Children Ages 9 to 11 | Phase2 | Acne Vulgaris | Completed | 2009-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00853970 | Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract… | Phase3 | Pain | Completed | 2009-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00854061 | Study of T-PRED(TM) Compared to Pred Forte(R) II | Phase3 | Cataract | Completed | 2009-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00907257 | A Study of Different Use Regimens Using Two Acne Treatments | Phase4 | Acne Vulgaris | Completed | 2009-02-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00907335 | A Study of Acne Treatment in Children Ages 9 to 11 | Phase2 | Acne Vulgaris | Completed | 2009-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00817557 | Use of Loteprednol for Contact Lens Intolerance and Dryness | Phase4 | Contact Lenses Dryness | Unknown | 2009-01-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00817557 | Use of Loteprednol for Contact Lens Intolerance and Dryness | Phase4 | Contact Lenses Dryness | Unknown | 2009-01-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00804141 | Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induce… | Phase3 | Constipation | Completed | 2008-12-03 | 2010-09-20 | ClinicalTrials.gov |
| NCT00804141 | Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induce… | Phase3 | Constipation | Completed | 2008-12-03 | 2010-09-20 | ClinicalTrials.gov |
| NCT00929916 | Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy | — | Colonoscopy | Completed | 2008-12-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00929916 | Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy | — | Colonoscopy | Completed | 2008-12-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00804726 | Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular … | Na | Cataract | Terminated | 2008-11-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00804726 | Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular … | Na | Cataract | Terminated | 2008-11-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00784641 | A Product Performance Evaluation of a Novel Contact Lens for Daily Disposable U… | Na | Myopia | Completed | 2008-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00784641 | A Product Performance Evaluation of a Novel Contact Lens for Daily Disposable U… | Na | Myopia | Completed | 2008-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00795327 | Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring | Na | Acne Vulgaris | Completed | 2008-10-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00769886 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challeng… | Phase3 | Allergic Conjunctivitis | Completed | 2008-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00902850 | One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compa… | Na | Myopia | Completed | 2008-10-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00795327 | Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring | Na | Acne Vulgaris | Completed | 2008-10-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00769886 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challeng… | Phase3 | Allergic Conjunctivitis | Completed | 2008-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00902850 | One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compa… | Na | Myopia | Completed | 2008-10-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00743912 | Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Hea… | Phase1 | Pharmacokinetic | Completed | 2008-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00768885 | Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs. | Na | Myopia | Completed | 2008-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00768885 | Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs. | Na | Myopia | Completed | 2008-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00743912 | Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Hea… | Phase1 | Pharmacokinetic | Completed | 2008-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00758784 | Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease | Phase2 | Dry Eye Disease | Completed | 2008-08-13 | 2009-01-14 | ClinicalTrials.gov |
| NCT00758784 | Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease | Phase2 | Dry Eye Disease | Completed | 2008-08-13 | 2009-01-14 | ClinicalTrials.gov |
| NCT00769808 | Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatme… | Na | Myopia | Completed | 2008-08-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00769808 | Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatme… | Na | Myopia | Completed | 2008-08-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00710879 | Evaluation of a Multi-Purpose Solution | Na | Contact Lens Solutions | Completed | 2008-07-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00724126 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) | Phase3 | Non-Constipation Irritable Bowel Syndrome | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00724126 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) | Phase3 | Non-Constipation Irritable Bowel Syndrome | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00710879 | Evaluation of a Multi-Purpose Solution | Na | Contact Lens Solutions | Completed | 2008-07-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00731679 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) | Phase3 | Non-Constipation Irritable Bowel Syndrome | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00731679 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) | Phase3 | Non-Constipation Irritable Bowel Syndrome | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00672139 | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Pati… | Phase4 | Opioid-Induced Constipation | Completed | 2008-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00672139 | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Pati… | Phase4 | Opioid-Induced Constipation | Completed | 2008-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00679432 | (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix Sy… | Phase3 | Ulcerative Colitis | Completed | 2008-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00679380 | (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix Sy… | Phase3 | Ulcerative Colitis | Completed | 2008-06-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00672477 | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced … | Phase4 | Opioid-Induced Constipation | Completed | 2008-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00679380 | (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix Sy… | Phase3 | Ulcerative Colitis | Completed | 2008-06-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00703781 | Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery | Phase3 | Cataract | Completed | 2008-06-01 | — | ClinicalTrials.gov |
| NCT00672477 | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced … | Phase4 | Opioid-Induced Constipation | Completed | 2008-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00705159 | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Bl… | Phase4 | Conjunctivitis | Completed | 2008-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00699153 | Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inf… | Phase3 | Ocular Inflammation | Completed | 2008-06-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00705159 | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Bl… | Phase4 | Conjunctivitis | Completed | 2008-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00704418 | Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery | Phase3 | Cataract | Completed | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00703781 | Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery | Phase3 | Cataract | Completed | 2008-06-01 | — | ClinicalTrials.gov |
| NCT00699153 | Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inf… | Phase3 | Ocular Inflammation | Completed | 2008-06-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00679432 | (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix Sy… | Phase3 | Ulcerative Colitis | Completed | 2008-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00704418 | Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery | Phase3 | Cataract | Completed | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00699803 | Study of T-PRED(TM) Compared to Pred Forte(R) | Phase2 | Cataract | Completed | 2008-05-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00699803 | Study of T-PRED(TM) Compared to Pred Forte(R) | Phase2 | Cataract | Completed | 2008-05-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00904904 | Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation … | Phase4 | Cataract | Completed | 2008-04-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00658996 | Product Performance of a Toric Contact Lens | Na | Myopia | Completed | 2008-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00658996 | Product Performance of a Toric Contact Lens | Na | Myopia | Completed | 2008-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00904904 | Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation … | Phase4 | Cataract | Completed | 2008-04-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00667004 | Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease | Phase2 | Dry Eye Disease | Completed | 2008-03-22 | 2008-09-12 | ClinicalTrials.gov |
| NCT00667004 | Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease | Phase2 | Dry Eye Disease | Completed | 2008-03-22 | 2008-09-12 | ClinicalTrials.gov |
| NCT00645671 | Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Infla… | Phase3 | Ocular Inflammation | Completed | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00645671 | Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Infla… | Phase3 | Ocular Inflammation | Completed | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00636363 | Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to C… | Na | Contact Lens Solutions | Completed | 2008-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00636363 | Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to C… | Na | Contact Lens Solutions | Completed | 2008-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00636194 | Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon Opti… | Na | Adverse Effect of Contact Lens Solution | Completed | 2008-02-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00622375 | PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers | Phase1 | Healthy | Completed | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00636194 | Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon Opti… | Na | Adverse Effect of Contact Lens Solution | Completed | 2008-02-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01272271 | Safety of Overnight Corneal Reshaping Lenses | — | Keratitis | Completed | 2008-02-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00640341 | Comparative Performance of PureVision, Acuvue Oasys and O2Optix | Phase4 | Myopia | Completed | 2008-02-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01272271 | Safety of Overnight Corneal Reshaping Lenses | — | Keratitis | Completed | 2008-02-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00622375 | PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers | Phase1 | Healthy | Completed | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00640341 | Comparative Performance of PureVision, Acuvue Oasys and O2Optix | Phase4 | Myopia | Completed | 2008-02-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00714714 | Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opp… | Phase4 | Acne Vulgaris | Completed | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00714714 | Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opp… | Phase4 | Acne Vulgaris | Completed | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00693225 | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis… | Phase4 | Erosive Esophagitis | Completed | 2008-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00605644 | Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chroni… | Phase2 | Constipation | Completed | 2008-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00605644 | Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chroni… | Phase2 | Constipation | Completed | 2008-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00693225 | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis… | Phase4 | Erosive Esophagitis | Completed | 2008-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00661687 | Comparative Performance of PureVision Lens Designs | Phase3 | Myopia | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00867100 | Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ph… | Phase1 | Psoriasis | Completed | 2007-12-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00661687 | Comparative Performance of PureVision Lens Designs | Phase3 | Myopia | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00595101 | A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angl… | Phase2 | Primary Open Angle Glaucoma | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00595101 | A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angl… | Phase2 | Primary Open Angle Glaucoma | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00867100 | Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ph… | Phase1 | Psoriasis | Completed | 2007-12-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00581659 | Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions | — | Astigmatism | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00581659 | Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions | — | Astigmatism | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00528970 | A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative … | Phase3 | Ileus | Completed | 2007-10-17 | 2008-02-05 | ClinicalTrials.gov |
| NCT00528970 | A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative … | Phase3 | Ileus | Completed | 2007-10-17 | 2008-02-05 | ClinicalTrials.gov |
| NCT00586664 | Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allerg… | Phase3 | Allergic Conjunctivitis | Completed | 2007-10-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00547586 | Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chroni… | Phase2 | Constipation | Completed | 2007-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00586664 | Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allerg… | Phase3 | Allergic Conjunctivitis | Completed | 2007-10-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00585975 | Efficacy and Safety of Bromfenac Ophthalmic Solution | Phase2 | Cataract Surgery | Completed | 2007-10-01 | — | ClinicalTrials.gov |
| NCT00547898 | Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Tr… | Phase3 | HIV Associated Diarrhea | Completed | 2007-10-01 | 2011-07-11 | ClinicalTrials.gov |
| NCT00533910 | Rifaximin in Minimal Hepatic Encephalopathy | Na | Hepatic Encephalopathy | Completed | 2007-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00585975 | Efficacy and Safety of Bromfenac Ophthalmic Solution | Phase2 | Cataract Surgery | Completed | 2007-10-01 | — | ClinicalTrials.gov |
| NCT00547898 | Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Tr… | Phase3 | HIV Associated Diarrhea | Completed | 2007-10-01 | 2011-07-11 | ClinicalTrials.gov |
| NCT00547586 | Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chroni… | Phase2 | Constipation | Completed | 2007-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00533910 | Rifaximin in Minimal Hepatic Encephalopathy | Na | Hepatic Encephalopathy | Completed | 2007-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00529087 | Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Const… | Phase3 | Constipation | Completed | 2007-08-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00520260 | Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase | Phase4 | Dry Eye Disease | Completed | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00529087 | Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Const… | Phase3 | Constipation | Completed | 2007-08-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00520260 | Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase | Phase4 | Dry Eye Disease | Completed | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00505583 | Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy | Phase1 | Methadone-maintenance Subjects | Withdrawn | 2007-07-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00505583 | Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy | Phase1 | Methadone-maintenance Subjects | Withdrawn | 2007-07-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00491166 | Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic… | Phase1 | Diabetic Macular Edema | Unknown | 2007-06-01 | — | ClinicalTrials.gov |
| NCT00492622 | Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastrop… | Phase4 | Gastroparesis | Completed | 2007-06-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00491166 | Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic… | Phase1 | Diabetic Macular Edema | Unknown | 2007-06-01 | — | ClinicalTrials.gov |
| NCT00487474 | A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCUL… | — | Mid Facial Contour Deficiencies | Completed | 2007-06-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00492622 | Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastrop… | Phase4 | Gastroparesis | Completed | 2007-06-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00487474 | A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCUL… | — | Mid Facial Contour Deficiencies | Completed | 2007-06-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01120418 | Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered… | Phase1 | Healthy | Completed | 2007-05-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01120418 | Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered… | Phase1 | Healthy | Completed | 2007-05-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00464802 | Study Evaluating the Safety and Tolerability of a New Intravenous Formulation o… | Phase1 | Healthy | Completed | 2007-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00464802 | Study Evaluating the Safety and Tolerability of a New Intravenous Formulation o… | Phase1 | Healthy | Completed | 2007-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00686920 | Safety and Tolerability Study of Rifaximin in Participants With a History of He… | Phase3 | Hepatic Encephalopathy | Completed | 2007-03-07 | 2010-12-08 | ClinicalTrials.gov |
| NCT00686920 | Safety and Tolerability Study of Rifaximin in Participants With a History of He… | Phase3 | Hepatic Encephalopathy | Completed | 2007-03-07 | 2010-12-08 | ClinicalTrials.gov |
| NCT00444158 | Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour I… | Phase1 | Constipation | Completed | 2007-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00443872 | Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experienci… | Phase4 | Parkinson's Disease | Completed | 2007-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00441883 | Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel … | Phase2 | Primary Open Angle Glaucoma | Completed | 2007-03-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00434395 | Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Su… | Phase1 | Healthy | Completed | 2007-03-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00446134 | Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (… | Phase2 | Chronic Hepatitis C | Completed | 2007-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00447811 | Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance | Phase1 | Methadone-maintenance Subjects | Completed | 2007-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00447811 | Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance | Phase1 | Methadone-maintenance Subjects | Completed | 2007-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00446134 | Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (… | Phase2 | Chronic Hepatitis C | Completed | 2007-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00443872 | Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experienci… | Phase4 | Parkinson's Disease | Completed | 2007-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00434395 | Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Su… | Phase1 | Healthy | Completed | 2007-03-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00441883 | Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel … | Phase2 | Primary Open Angle Glaucoma | Completed | 2007-03-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00444158 | Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour I… | Phase1 | Constipation | Completed | 2007-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01366378 | Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX | Phase1 | Healthy Adult Subjects | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00447551 | Canadian Aesthetic Experience With Sculptra Therapy | Phase4 | Skin Aging | Completed | 2007-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01366378 | Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX | Phase1 | Healthy Adult Subjects | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00447577 | Zylet vs TobraDex in Blepharokeratoconjunctivitis | Phase4 | Blepharokeratoconjunctivitis | Completed | 2007-01-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00447577 | Zylet vs TobraDex in Blepharokeratoconjunctivitis | Phase4 | Blepharokeratoconjunctivitis | Completed | 2007-01-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00447551 | Canadian Aesthetic Experience With Sculptra Therapy | Phase4 | Skin Aging | Completed | 2007-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00387309 | Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus | Phase3 | Post Operative Bowel Dysfunction | Completed | 2006-12-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00387309 | Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus | Phase3 | Post Operative Bowel Dysfunction | Completed | 2006-12-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00420628 | Pediatric Zylet Safety and Efficacy Study | Phase4 | Chalazion | Completed | 2006-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00423007 | Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Sub… | Phase3 | Allergic Conjunctivitis | Completed | 2006-11-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00423007 | Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Sub… | Phase3 | Allergic Conjunctivitis | Completed | 2006-11-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00420628 | Pediatric Zylet Safety and Efficacy Study | Phase4 | Chalazion | Completed | 2006-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00407043 | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiatio… | Phase4 | Dry Eye Disease | Completed | 2006-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00407043 | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiatio… | Phase4 | Dry Eye Disease | Completed | 2006-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00461526 | Diarrhea Predominant Irritable Bowel Syndrome in Females | Phase2 | Irritable Bowel Syndrome | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT01366365 | Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrex… | Phase1 | Healthy Adults | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00486031 | Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study | Phase3 | Inflammatory Bowel Disease | Completed | 2006-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00461526 | Diarrhea Predominant Irritable Bowel Syndrome in Females | Phase2 | Irritable Bowel Syndrome | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00407589 | Systemic Pharmacokinetics of BOL-303224-A | Phase1 | Conjunctivitis, Bacterial | Completed | 2006-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00398502 | Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations… | Phase1 | Metahdone-maintenance Subjects | Completed | 2006-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT01137955 | Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Dise… | Na | Celiac Disease | Completed | 2006-10-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00398502 | Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations… | Phase1 | Metahdone-maintenance Subjects | Completed | 2006-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00407589 | Systemic Pharmacokinetics of BOL-303224-A | Phase1 | Conjunctivitis, Bacterial | Completed | 2006-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01366365 | Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrex… | Phase1 | Healthy Adults | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT01137955 | Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Dise… | Na | Celiac Disease | Completed | 2006-10-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00486031 | Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study | Phase3 | Inflammatory Bowel Disease | Completed | 2006-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00605826 | A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment… | Na | Fecal Incontinence | Completed | 2006-09-07 | 2009-11-23 | ClinicalTrials.gov |
| NCT00605826 | A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment… | Na | Fecal Incontinence | Completed | 2006-09-07 | 2009-11-23 | ClinicalTrials.gov |
| NCT00347646 | A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment… | Phase1 | Vitreoretinal Traction Syndrome | Terminated | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00347646 | A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment… | Phase1 | Vitreoretinal Traction Syndrome | Terminated | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00838045 | Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intrao… | Phase4 | Cataract | Completed | 2006-09-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00838045 | Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intrao… | Phase4 | Cataract | Completed | 2006-09-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00387985 | Bioequivalence Study in Healthy Volunteers | Phase1 | Healthy | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00418678 | A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemoth… | Phase4 | Nausea and Vomiting | Terminated | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00366431 | Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunc… | Phase2 | Constipation | Completed | 2006-08-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00387985 | Bioequivalence Study in Healthy Volunteers | Phase1 | Healthy | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00364689 | RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Control… | Phase3 | Hepatic Encephalopathy | Terminated | 2006-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00364689 | RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Control… | Phase3 | Hepatic Encephalopathy | Terminated | 2006-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00418678 | A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemoth… | Phase4 | Nausea and Vomiting | Terminated | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00366431 | Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunc… | Phase2 | Constipation | Completed | 2006-08-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00348348 | A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment o… | Phase3 | Acute Bacterial Conjunctivitis | Completed | 2006-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00347932 | A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of … | Phase3 | Acute Bacterial Conjunctivitis | Completed | 2006-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00348348 | A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment o… | Phase3 | Acute Bacterial Conjunctivitis | Completed | 2006-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00347932 | A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of … | Phase3 | Acute Bacterial Conjunctivitis | Completed | 2006-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00408174 | Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative C… | Phase3 | Inflammatory Bowel Disease | Completed | 2006-05-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00408174 | Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative C… | Phase3 | Inflammatory Bowel Disease | Completed | 2006-05-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00348439 | Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment | Phase2 | Vitreoretinal Traction Syndrome | Terminated | 2006-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00348439 | Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment | Phase2 | Vitreoretinal Traction Syndrome | Terminated | 2006-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00311350 | Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects | Phase1 | Postoperative Complications | Completed | 2006-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01367535 | Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan | Phase1 | Healthy Adults | Completed | 2006-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01367535 | Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan | Phase1 | Healthy Adults | Completed | 2006-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00311350 | Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects | Phase1 | Postoperative Complications | Completed | 2006-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00298038 | A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing H… | Phase3 | Hepatic Encephalopathy | Completed | 2005-12-19 | 2008-08-15 | ClinicalTrials.gov |
| NCT00298038 | A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing H… | Phase3 | Hepatic Encephalopathy | Completed | 2005-12-19 | 2008-08-15 | ClinicalTrials.gov |
| NCT00384410 | Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Mali… | Phase2 | Pain | Unknown | 2005-12-01 | — | ClinicalTrials.gov |
| NCT00281502 | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Ence… | Phase2 | Hepatic Encephalopathy | Unknown | 2005-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00328380 | Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S. | Phase3 | Diarrhea | Completed | 2005-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00269412 | Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Tr… | Phase2 | Irritable Bowel Syndrome | Completed | 2005-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00281502 | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Ence… | Phase2 | Hepatic Encephalopathy | Unknown | 2005-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00269412 | Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Tr… | Phase2 | Irritable Bowel Syndrome | Completed | 2005-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00269399 | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Diffi… | Phase3 | Clostridium Infections | Completed | 2005-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00384410 | Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Mali… | Phase2 | Pain | Unknown | 2005-12-01 | — | ClinicalTrials.gov |
| NCT00235755 | Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in E… | Phase3 | Seizures | Completed | 2005-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00328380 | Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S. | Phase3 | Diarrhea | Completed | 2005-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00235755 | Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in E… | Phase3 | Seizures | Completed | 2005-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00269399 | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Diffi… | Phase3 | Clostridium Infections | Completed | 2005-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00305383 | Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepa… | Phase2 | Hepatitis C, Chronic | Terminated | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00305383 | Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepa… | Phase2 | Hepatitis C, Chronic | Terminated | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00360932 | Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study) | — | Facial Lipoatrophy | Completed | 2005-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00360932 | Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study) | — | Facial Lipoatrophy | Completed | 2005-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00365677 | A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractiv… | Na | Myopia | Completed | 2005-10-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00365677 | A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractiv… | Na | Myopia | Completed | 2005-10-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00232596 | Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Ref… | Phase3 | Seizures | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00232596 | Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Ref… | Phase3 | Seizures | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00347594 | A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI) | Na | Healthy | Completed | 2005-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00347594 | A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI) | Na | Healthy | Completed | 2005-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00121511 | The Effect of Efudex Treatment on Photoaged Skin | Na | Photo-aging | Completed | 2005-07-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00198523 | A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredF… | Phase3 | Eye Infections | Completed | 2005-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00198471 | Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreo… | Phase2 | Vitreous Detachment | Completed | 2005-07-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00121511 | The Effect of Efudex Treatment on Photoaged Skin | Na | Photo-aging | Completed | 2005-07-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00198471 | Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreo… | Phase2 | Vitreous Detachment | Completed | 2005-07-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00198523 | A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredF… | Phase3 | Eye Infections | Completed | 2005-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00348205 | A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix S… | Na | Hyperopia | Completed | 2005-06-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01367483 | Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX | Phase1 | Healthy Male Volunteers | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT01367483 | Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX | Phase1 | Healthy Male Volunteers | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00348205 | A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix S… | Na | Hyperopia | Completed | 2005-06-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00230490 | Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-… | Phase2 | Hepatitis B, Chronic | Terminated | 2005-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00230490 | Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-… | Phase2 | Hepatitis B, Chronic | Terminated | 2005-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00198536 | Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye S… | Phase2 | Dry Eye Syndromes | Completed | 2005-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00198536 | Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye S… | Phase2 | Dry Eye Syndromes | Completed | 2005-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00162734 | Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy | Phase3 | Chronic Hepatitis C | Completed | 2005-02-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00162734 | Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy | Phase3 | Chronic Hepatitis C | Completed | 2005-02-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00532961 | Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex | Phase4 | Inflammation | Completed | 2005-02-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00532961 | Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex | Phase4 | Inflammation | Completed | 2005-02-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00744016 | Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerat… | Phase3 | Ulcerative Colitis | Completed | 2004-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00744016 | Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerat… | Phase3 | Ulcerative Colitis | Completed | 2004-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00767728 | Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis | Phase3 | Ulcerative Colitis | Completed | 2004-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00101725 | A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2004-12-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00101725 | A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2004-12-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00622908 | Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis | Phase2 | Bacterial Conjunctivitis | Completed | 2004-12-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00622908 | Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis | Phase2 | Bacterial Conjunctivitis | Completed | 2004-12-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00212134 | Infant Aphakia Treatment Study (IATS) | Na | Congenital Cataract | Completed | 2004-12-01 | 2020-08-31 | ClinicalTrials.gov |
| NCT00212134 | Infant Aphakia Treatment Study (IATS) | Na | Congenital Cataract | Completed | 2004-12-01 | 2020-08-31 | ClinicalTrials.gov |
| NCT00767728 | Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis | Phase3 | Ulcerative Colitis | Completed | 2004-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00198549 | Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of O… | Phase4 | Pain | Completed | 2004-09-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00198549 | Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of O… | Phase4 | Pain | Completed | 2004-09-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00444353 | DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Ter… | Phase3 | Nasolabial Fold Wrinkles | Completed | 2004-08-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00444353 | DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Ter… | Phase3 | Nasolabial Fold Wrinkles | Completed | 2004-08-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00198458 | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Phase1 | Drug Hypersensitivity | Completed | 2004-07-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00198458 | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Phase1 | Drug Hypersensitivity | Completed | 2004-07-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00086541 | Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy | Phase3 | Chronic Hepatitis C | Completed | 2004-06-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00444210 | DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles | Phase3 | Nasolabial Fold Wrinkles | Completed | 2004-06-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00292344 | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Phase4 | Travelers' Diarrhea | Completed | 2004-06-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00230503 | Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B | Phase2 | Hepatitis B, Chronic | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00093093 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are T… | Phase3 | Chronic Hepatitis C | Completed | 2004-06-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00086541 | Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy | Phase3 | Chronic Hepatitis C | Completed | 2004-06-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00444210 | DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles | Phase3 | Nasolabial Fold Wrinkles | Completed | 2004-06-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00292344 | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Phase4 | Travelers' Diarrhea | Completed | 2004-06-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00230503 | Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B | Phase2 | Hepatitis B, Chronic | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00093093 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are T… | Phase3 | Chronic Hepatitis C | Completed | 2004-06-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00543296 | Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis … | Phase4 | Uveitis | Completed | 2004-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00198419 | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Phase1 | Drug Hypersensitivity | Completed | 2004-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT01367509 | Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjec… | Phase1 | Renal Impairment | Completed | 2004-03-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT01367509 | Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjec… | Phase1 | Renal Impairment | Completed | 2004-03-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT01367613 | Open-Label Treatment Extension of Protocol MNTX 302 | Phase3 | Terminal Illness | Completed | 2004-03-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT01367613 | Open-Label Treatment Extension of Protocol MNTX 302 | Phase3 | Terminal Illness | Completed | 2004-03-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00543296 | Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis … | Phase4 | Uveitis | Completed | 2004-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00198419 | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Phase1 | Drug Hypersensitivity | Completed | 2004-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00786565 | Clinical Evaluation of a New Aspheric Intraocular Lens. | Phase4 | Cataract | Completed | 2004-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00786565 | Clinical Evaluation of a New Aspheric Intraocular Lens. | Phase4 | Cataract | Completed | 2004-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00230958 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are T… | Phase3 | Chronic Hepatitis C | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00230958 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are T… | Phase3 | Chronic Hepatitis C | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT01367548 | Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Il… | Phase2 | Postoperative Ileus | Completed | 2003-07-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00259155 | Rifaximin for the Treatment of Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2003-07-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01367548 | Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Il… | Phase2 | Postoperative Ileus | Completed | 2003-07-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00259155 | Rifaximin for the Treatment of Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2003-07-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00576459 | Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients… | Phase2 | Diabetic Macular Edema | Completed | 2003-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00576459 | Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients… | Phase2 | Diabetic Macular Edema | Completed | 2003-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT01367600 | Open-Label Treatment Extension of Protocol MNTX 301 | Phase3 | Terminal Illness | Completed | 2003-02-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00401362 | A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients | Phase3 | Advanced Illness Patients With Opioid Induced Constipation | Completed | 2003-02-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT01367600 | Open-Label Treatment Extension of Protocol MNTX 301 | Phase3 | Terminal Illness | Completed | 2003-02-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00401362 | A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients | Phase3 | Advanced Illness Patients With Opioid Induced Constipation | Completed | 2003-02-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT01368562 | Compassionate Use Study of Methylnaltrexone | Na | Opioid-induced Constipation | Completed | 2003-01-24 | 2008-06-02 | ClinicalTrials.gov |
| NCT01368562 | Compassionate Use Study of Methylnaltrexone | Na | Opioid-induced Constipation | Completed | 2003-01-24 | 2008-06-02 | ClinicalTrials.gov |
| NCT00636493 | Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) | Early_Phase1 | Retinal Vein Occlusion | Completed | 2002-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00952614 | A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Re… | Na | Central Retinal Vein Occlusion | Completed | 2002-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00952614 | A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Re… | Na | Central Retinal Vein Occlusion | Completed | 2002-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00636493 | Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) | Early_Phase1 | Retinal Vein Occlusion | Completed | 2002-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00348452 | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl… | Phase3 | Chronic Pain | Completed | 2002-09-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00348452 | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl… | Phase3 | Chronic Pain | Completed | 2002-09-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT01367496 | Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnalt… | Phase1 | Healthy Subjects | Completed | 2002-06-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT01367496 | Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnalt… | Phase1 | Healthy Subjects | Completed | 2002-06-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00456482 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant | Phase2 | Non-infectious Uveitis | Terminated | 2002-05-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00456482 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant | Phase2 | Non-infectious Uveitis | Terminated | 2002-05-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT01367574 | Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction | Phase2 | Bowel Dysfunction | Completed | 2002-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT01367574 | Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction | Phase2 | Bowel Dysfunction | Completed | 2002-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00468871 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardi… | Phase2 | Non-infectious Uveitis | Completed | 2002-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00468871 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardi… | Phase2 | Non-infectious Uveitis | Completed | 2002-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00325858 | A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, … | Phase3 | Chronic Pain | Completed | 2002-01-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00325858 | A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, … | Phase3 | Chronic Pain | Completed | 2002-01-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00502541 | Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Ede… | Phase2 | Diabetic Macular Edema | Completed | 2001-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00502541 | Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Ede… | Phase2 | Diabetic Macular Edema | Completed | 2001-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00407082 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants | Phase2 | Noninfectious Posterior Uveitis | Completed | 2000-12-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00407082 | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants | Phase2 | Noninfectious Posterior Uveitis | Completed | 2000-12-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00347724 | A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Ver… | Phase3 | Chronic Pain | Completed | 2000-11-01 | 2001-11-01 | ClinicalTrials.gov |
| NCT00347724 | A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Ver… | Phase3 | Chronic Pain | Completed | 2000-11-01 | 2001-11-01 | ClinicalTrials.gov |
| NCT00348010 | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Ver… | Phase3 | Chronic Pain | Completed | 2000-11-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00348010 | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Ver… | Phase3 | Chronic Pain | Completed | 2000-11-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01208948 | Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema | Phase3 | Diabetes Mellitus | Completed | 2000-07-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01208948 | Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema | Phase3 | Diabetes Mellitus | Completed | 2000-07-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00006411 | Cornea Donor Study | Na | Corneal Disease | Completed | 2000-01-10 | 2014-07-01 | ClinicalTrials.gov |
| NCT00006411 | Cornea Donor Study | Na | Corneal Disease | Completed | 2000-01-10 | 2014-07-01 | ClinicalTrials.gov |
| NCT00198497 | Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage | Phase3 | Vitreous Hemorrhage | Completed | 1999-06-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00198497 | Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage | Phase3 | Vitreous Hemorrhage | Completed | 1999-06-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00198510 | Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage | Phase3 | Vitreous Hemorrhage | Completed | 1998-11-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00198510 | Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage | Phase3 | Vitreous Hemorrhage | Completed | 1998-11-01 | 2003-03-01 | ClinicalTrials.gov |
Total clinical trials: 888
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo® | Other | Phase PHASE4 | Dry Eye | RECRUITING | NCT07722624 |
| Placebo | Other | Phase PHASE2 | Functional Constipation (FC) | ACTIVE_NOT_RECRUITING | NCT07723924 |
| plecanatide | Other | Phase PHASE2 | Functional Constipation (FC) | ACTIVE_NOT_RECRUITING | NCT07723924 |
| Placebo | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Larsucosterol | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Timolol maleate 0.5% | Other | Phase PHASE2 | Glaucoma | COMPLETED | NCT07168902 |
| BL1107 High dose | Other | Phase PHASE2 | Glaucoma | COMPLETED | NCT07168902 |
| BL1107 Low dose | Other | Phase PHASE2 | Glaucoma | COMPLETED | NCT07168902 |
| BL1332 Placebo eye drops | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07717918 |
| BL1332 eye drops | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07717918 |
| Miebo | Other | Phase PHASE4 | Dry Eye | COMPLETED | NCT06346340 |
| Miebo four times per day | Other | Phase PHASE4 | Dry Eye Syndrome (DES) | RECRUITING | NCT07650708 |
| Fraxel® FTX Laser System | Other | Approved | Skin Resurfacing | ACTIVE_NOT_RECRUITING | NCT07214272 |
| BCMC lens | Other | Approved | Myopia | ACTIVE_NOT_RECRUITING | NCT07511387 |
| enVista Aspire EA or Aspire Toric ETA IOLs | Other | Approved | Cataract | COMPLETED | NCT06594185 |
| Lumify® | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT06803654 |
| BTOS-HA | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT06803654 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| MX60E | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| An IOL with a slightly extended depth of focus | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| enVista® Aspire™ | Other | Approved | Cataract | TERMINATED | NCT06479148 |
| Nabilone | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00384410 |
| Rewetter | Other | Phase PHASE4 | Contact Lenses Dryness | UNKNOWN | NCT00817557 |
| Loteprednol | Other | Phase PHASE4 | Contact Lenses Dryness | UNKNOWN | NCT00817557 |
| Cesamet | Other | Phase PHASE4 | Nausea and Vomiting | TERMINATED | NCT00418678 |
| Cesamet | Other | Phase PHASE4 | Nausea and Vomiting | TERMINATED | NCT00418678 |
| Placebo | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01140841 |
| Fipamezole ODT | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01140841 |
| Placebo | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01140841 |
| Fipamezole ODT | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01140841 |
| Rifaximin | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00259155 |
| ketorolac | Other | Phase PHASE4 | Dry Eye Disease | COMPLETED | NCT00520260 |
| bromfenac | Other | Phase PHASE4 | Dry Eye Disease | COMPLETED | NCT00520260 |
| Rifaximin and loperamide | Other | Phase PHASE4 | Travelers' Diarrhea | COMPLETED | NCT00292344 |
| 1,2 dithiolane 3 valeric acid | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01208948 |
| Rifaximin (drug) | Drug | Phase PHASE2 | Hepatic Encephalopathy | UNKNOWN | NCT00281502 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Ciba's Multi-Purpose Solution | Other | Approved | Ocular Discomfort | COMPLETED | NCT01024751 |
| Bausch & Lomb Multi-Purpose Solution | Other | Approved | Ocular Discomfort | COMPLETED | NCT01024751 |
| vehicle | Other | Phase PHASE4 | Chalazion | COMPLETED | NCT00420628 |
| loteprednol etabonate/tobramycin opthalmic suspension | Other | Phase PHASE4 | Chalazion | COMPLETED | NCT00420628 |
| vigamox | Other | Phase PHASE4 | Corneal Health | COMPLETED | NCT01455233 |
| besivance | Other | Phase PHASE4 | Corneal Health | COMPLETED | NCT01455233 |
| standard of care laser photocoagulation | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00576459 |
| 2.1 mg fluocinolone acetonide intravitreal implant | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00576459 |
| 0.59 mg fluocinolone acetonide intravitreal implant | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00576459 |
| Dexamethasone 0.1% and tobramycin 0.3% | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT00532961 |
| Loteprednol etabonate 0.5% and tobramycin 0.3% | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT00532961 |
| corticosteroids and immunosuppressants | Other | Phase PHASE2 | Non-infectious Uveitis | COMPLETED | NCT00468871 |
| fluocinolone acetonide intravitreal implant | Other | Phase PHASE2 | Non-infectious Uveitis | COMPLETED | NCT00468871 |
| corticosteroids and immunosuppressants | Other | Phase PHASE2 | Non-infectious Uveitis | COMPLETED | NCT00468871 |
| fluocinolone acetonide intravitreal implant | Other | Phase PHASE2 | Non-infectious Uveitis | COMPLETED | NCT00468871 |
| Fluocinolone Acetonide 2.1mg | Other | Phase PHASE2 | Non-infectious Uveitis | TERMINATED | NCT00456482 |
| Fluocinolone Acetonide 0.59mg | Other | Phase PHASE2 | Non-infectious Uveitis | TERMINATED | NCT00456482 |
| Fluocinolone Acetonide 2.1mg | Other | Phase PHASE2 | Non-infectious Uveitis | TERMINATED | NCT00456482 |
| Fluocinolone Acetonide 0.59mg | Other | Phase PHASE2 | Non-infectious Uveitis | TERMINATED | NCT00456482 |
| Fluocinolone acetonide 2.1mg | Other | Phase PHASE2 | Noninfectious Posterior Uveitis | COMPLETED | NCT00407082 |
| fluocinolone acetonide intravitreal implant | Other | Phase PHASE2 | Noninfectious Posterior Uveitis | COMPLETED | NCT00407082 |
| The Bausch & Lomb Zyoptix Tissue Saving algorithm | Other | Approved | Myopia | COMPLETED | NCT00365677 |
| The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm | Other | Approved | Myopia | COMPLETED | NCT00365677 |
| 217z Laser | Other | Approved | Myopia | WITHDRAWN | NCT00347997 |
| 217z Laser | Other | Approved | Myopia | WITHDRAWN | NCT00347997 |
| Besifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905762 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905762 |
| Gatifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905762 |
| The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00838045 |
| Tobramycin and dexamethasone ophthalmic suspension | Other | Phase PHASE4 | Blepharokeratoconjunctivitis | COMPLETED | NCT00447577 |
| Loteprednol etabonate and tobramycin ophthalmic suspension | Other | Phase PHASE4 | Blepharokeratoconjunctivitis | COMPLETED | NCT00447577 |
| BOL-303224-A | Other | Phase PHASE1 | Conjunctivitis, Bacterial | COMPLETED | NCT00407589 |
| BOL-303224-A | Other | Phase PHASE1 | Conjunctivitis, Bacterial | COMPLETED | NCT00407589 |
| Akreos Adapt in fellow operated eye. | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00786565 |
| Advanced Akreos Adapt in one operated eye. | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00786565 |
| Alternate Design of the PureVision Contact Lens. | Other | Phase PHASE3 | Myopia | COMPLETED | NCT00661687 |
| Currently Marketed PureVision Contact Lens. | Other | Phase PHASE3 | Myopia | COMPLETED | NCT00661687 |
| Alternate Design of the PureVision Contact Lens. | Other | Phase PHASE3 | Myopia | COMPLETED | NCT00661687 |
| Currently Marketed PureVision Contact Lens. | Other | Phase PHASE3 | Myopia | COMPLETED | NCT00661687 |
| Ciba Vision Focus Dailies Toric Contact Lens | Other | Approved | Myopia | COMPLETED | NCT00658996 |
| SofLens DD Toric | Other | Approved | Myopia | COMPLETED | NCT00658996 |
| O2Optix Contact lens | Other | Phase PHASE4 | Myopia | COMPLETED | NCT00640341 |
| Acuvue Oasys Contact Lens | Other | Phase PHASE4 | Myopia | COMPLETED | NCT00640341 |
| PureVision Contact Lens | Other | Phase PHASE4 | Myopia | COMPLETED | NCT00640341 |
| gatifloxacin | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| moxifloxacin hydrochloride | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| Besifloxacin hydrochloride | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| gatifloxacin | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| moxifloxacin hydrochloride | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| Besifloxacin hydrochloride | Other | Phase PHASE1 | Cataract Extraction | COMPLETED | NCT00824070 |
| Bausch & Lomb Multi-Purpose Solution | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00710879 |
| Alcon OptiFree Replenish Multipurpose Solution | Other | Approved | Adverse Effect of Contact Lens Solution | COMPLETED | NCT00636194 |
| Bausch & Lomb Multipurpose Solution | Other | Approved | Adverse Effect of Contact Lens Solution | COMPLETED | NCT00636194 |
| Loteprednol Etabonate | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01010633 |
| Vehicle of Loteprednol Etabonate | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01010633 |
| Omeprazole/sodium bicarbonate | Other | Phase PHASE4 | Erosive Esophagitis | COMPLETED | NCT00693225 |
| Omeprazole/sodium bicarbonate | Other | Phase PHASE4 | Erosive Esophagitis | COMPLETED | NCT00693225 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Tretinoin Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01313728 |
| Dapsone plus Tretinoin Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01313728 |
| Adapalene/Benzoyl Peroxide Facial Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00952523 |
| Tretinoin Facial Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00952523 |
| Adapalene and Benzoyl peroxide | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00919191 |
| Tretinoin gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00919191 |
| Vehicle control | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT00907335 |
| Retin-A Micro 0.04% facial acne treatment | Drug | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT00907335 |
| Tretinoin gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00907257 |
| benzoyl peroxide wash | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00907257 |
| Tretinoin Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00714714 |
| Adapalene Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00714714 |
| Tobramycin and dexamethasone | Other | Phase PHASE3 | Conjunctivitis | COMPLETED | NCT01028027 |
| Loteprednol and tobramycin | Other | Phase PHASE3 | Conjunctivitis | COMPLETED | NCT01028027 |
| Vehicle of loteprednol etabonate | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01107405 |
| Loteprednol etabonate suspension | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01107405 |
| Loteprednol etabonate base (QID) | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01107405 |
| Loteprednol etabonate base (BID) | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01107405 |
| Loteprednol etabonate base (QD) | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01107405 |
| Vehicle (Placebo) | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00972777 |
| Besifloxacin | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00972777 |
| tramadol HCl ER; celecoxib | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT00348452 |
| Tramadol HCl ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT00348010 |
| Tramadol HCl ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT00347724 |
| Fipamezole ODT Cohort 2 | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01149811 |
| Fipamezole ODT | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01149811 |
| Fipamezole ODT Cohort 2 | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01149811 |
| Fipamezole ODT | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01149811 |
| Pergolide | Other | Preclinical | Parkinson Disease | NO_LONGER_AVAILABLE | NCT00624741 |
| Peginterferon alfa-2b | Other | Phase PHASE2 | Hepatitis C, Chronic | TERMINATED | NCT00305383 |
| Viramidine | Other | Phase PHASE2 | Hepatitis C, Chronic | TERMINATED | NCT00305383 |
| pegylated interferon alfa-2b | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| Ribavirin | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| Viramidine | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| pegylated interferon alfa-2b | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| Ribavirin | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| Viramidine | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00230958 |
| adefovir dipivoxyl | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT00230503 |
| pradefovir mesylate | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT00230503 |
| Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00162734 |
| pegylated interferon alfa-2a | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00093093 |
| Ribavirin | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00093093 |
| Viramidine | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00093093 |
| Ribavirin | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT00446134 |
| Taribavirin | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT00446134 |
| Ribavirin | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT00446134 |
| Taribavirin | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT00446134 |
| Besifloxacin Ophthalmic Suspension 0.6% | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01120418 |
| Besifloxacin Ophthalmic Suspension 0.6% | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01120418 |
| Ketorolac Ophthalmic Solution | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00904904 |
| Indomethacin ophthalmic solution | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00904904 |
| Placebo | Other | Phase PHASE3 | Premature Ejaculation | TERMINATED | NCT00983736 |
| Tramadol Hydrochloride | Other | Phase PHASE3 | Premature Ejaculation | TERMINATED | NCT00983736 |
| Tramadol Hydrochloride & Placebo | Other | Phase PHASE3 | Premature Ejaculation | TERMINATED | NCT00983151 |
| Tramadol Hydrochloride & Placebo | Other | Phase PHASE3 | Premature Ejaculation | TERMINATED | NCT00983151 |
| Tramadol HCl ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT00325858 |
| Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO) | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00825513 |
| Akreos Toric IOL | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00825513 |
| Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO) | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00825513 |
| Akreos Toric IOL | Other | Phase PHASE4 | Cataract | COMPLETED | NCT00825513 |
| Tecnis Multifocal IOL | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| ReSTOR | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| Crystalens AO | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| Tecnis Multifocal IOL | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| ReSTOR | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| Crystalens AO | Other | Phase PHASE4 | Cataract | COMPLETED | NCT01122576 |
| Vehicle | Other | Phase PHASE3 | Bacterial Conjunctivitis | TERMINATED | NCT01740388 |
| Besifloxacin | Other | Phase PHASE3 | Bacterial Conjunctivitis | TERMINATED | NCT01740388 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| rifaximin | Other | Phase PHASE1 | Minimal Hepatic Encephalopathy | COMPLETED | NCT01069133 |
| Rifaximin | Other | Phase PHASE1 | Minimal Hepatic Encephalopathy | COMPLETED | NCT01069133 |
| fluocinolone acetonide (Retisert Implant) | Other | Phase EARLY_PHASE1 | Retinal Vein Occlusion | COMPLETED | NCT00636493 |
| fluocinolone acetonide (Retisert Implant) | Other | Phase EARLY_PHASE1 | Retinal Vein Occlusion | COMPLETED | NCT00636493 |
| Placebo | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00704418 |
| Bromfenac | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00704418 |
| Placebo | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00704418 |
| Bromfenac | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00704418 |
| Placebo Comparator | Other | Phase PHASE3 | Pain | COMPLETED | NCT00853970 |
| Bromfenac Ophthalmic Solution | Other | Phase PHASE3 | Pain | COMPLETED | NCT00853970 |
| Placebo Comparator | Other | Phase PHASE3 | Pain | COMPLETED | NCT00853970 |
| Bromfenac Ophthalmic Solution | Other | Phase PHASE3 | Pain | COMPLETED | NCT00853970 |
| Bepotastine Besilate Ophthalmic Solution 1.0% | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00586664 |
| placebo comparator | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00586664 |
| Bepreve (bepotastine besilate ophthalmic solution) 1.5% | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00586664 |
| bromfenac ophthalmic solution | Other | Phase PHASE2 | Cataract Surgery | COMPLETED | NCT00585975 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00423007 |
| Bromfenac | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00423007 |
| Vehicle | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Ecabet 3.70% | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Ecabet 2.83% | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Vehicle | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Ecabet 3.70% | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Ecabet 2.83% | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT00198536 |
| Vitrase | Other | Phase PHASE1 | Drug Hypersensitivity | COMPLETED | NCT00198419 |
| Vitrase | Other | Phase PHASE1 | Drug Hypersensitivity | COMPLETED | NCT00198419 |
| Prednisolone | Other | Phase PHASE3 | Eye Infections | COMPLETED | NCT00198523 |
| Prednisolone and Tobramycin | Other | Phase PHASE3 | Eye Infections | COMPLETED | NCT00198523 |
| Prednisolone | Other | Phase PHASE3 | Eye Infections | COMPLETED | NCT00198523 |
| Prednisolone and Tobramycin | Other | Phase PHASE3 | Eye Infections | COMPLETED | NCT00198523 |
| Vitrase | Other | Phase PHASE3 | Vitreous Hemorrhage | COMPLETED | NCT00198510 |
| Vitrase | Other | Phase PHASE3 | Vitreous Hemorrhage | COMPLETED | NCT00198497 |
| Placebo | Other | Phase PHASE3 | Vitreous Hemorrhage | COMPLETED | NCT00198497 |
| Vitrase | Other | Phase PHASE2 | Vitreous Detachment | COMPLETED | NCT00198471 |
| Vitrase | Other | Phase PHASE2 | Vitreous Detachment | COMPLETED | NCT00198471 |
| PureVision 2 | Other | Approved | Myopia | COMPLETED | NCT00768885 |
| PureVision 1 | Other | Approved | Myopia | COMPLETED | NCT00768885 |
| Vitrase | Other | Phase PHASE1 | Drug Hypersensitivity | COMPLETED | NCT00198458 |
| Vitrase | Other | Phase PHASE1 | Drug Hypersensitivity | COMPLETED | NCT00198458 |
| Vitrase (ovine hyaluronidase) Lyophilized | Other | Phase PHASE4 | Pain | COMPLETED | NCT00198549 |
| Vehicle | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT01175590 |
| Besivance | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT01175590 |
| Vehicle | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT01175590 |
| Besivance | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT01175590 |
| PEG-ELS | Other | Approved | Hyponatremia | COMPLETED | NCT01299779 |
| PEG-SD | Other | Approved | Hyponatremia | COMPLETED | NCT01299779 |
| enVista | Other | Phase PHASE3 | Aphakia | COMPLETED | NCT01230060 |
| enVista | Other | Phase PHASE3 | Aphakia | COMPLETED | NCT01230060 |
| Vismed | Other | Approved | Dry Eye | WITHDRAWN | NCT01791426 |
| Artelac Rebalance | Other | Approved | Dry Eye | WITHDRAWN | NCT01791426 |
| Standard of Care | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00502541 |
| fluocinolone acetonide | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00502541 |
| Standard of Care | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00502541 |
| fluocinolone acetonide | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00502541 |
| Marketed daily disposable contact lens | Other | Approved | Myopia | COMPLETED | NCT01130974 |
| Bausch & Lomb contact lens | Other | Approved | Myopia | COMPLETED | NCT01130974 |
| Besifloxocin | Other | Phase PHASE4 | Blepharitis | COMPLETED | NCT01478256 |
| Erythromycin | Other | Phase PHASE4 | Blepharitis | COMPLETED | NCT01478256 |
| SofLens daily disposable contact lens | Other | Approved | Myopia | COMPLETED | NCT01365039 |
| Test, daily disposable contact lens | Other | Approved | Myopia | COMPLETED | NCT01365039 |
| Akreos MI Five-O | Other | Approved | Cataract | TERMINATED | NCT00804726 |
| Zyoptix Diagnostic Workstation (ZDW) | Other | Approved | Healthy | COMPLETED | NCT00347594 |
| Next Generation Diagnostic Instrument (NGDI) | Device | Approved | Healthy | COMPLETED | NCT00347594 |
| Ciba Vision soft contact lens | Other | Approved | Myopia | COMPLETED | NCT01412983 |
| Bausch & Lomb Test lens | Other | Approved | Myopia | COMPLETED | NCT01412983 |
| Air Optix Aqua Lens | Other | Approved | Myopia | COMPLETED | NCT01309100 |
| Acuvue Oasys Lens | Other | Approved | Myopia | COMPLETED | NCT01309100 |
| Investigational Lens | Other | Approved | Myopia | COMPLETED | NCT01309100 |
| Air Optix Aqua | Other | Approved | Myopia | COMPLETED | NCT01131130 |
| Acuvue Oasys Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01131130 |
| Investigational contact lens | Other | Approved | Myopia | COMPLETED | NCT01131130 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT01367249 |
| Bromfenac Ophthalmic Solution | Other | Phase PHASE3 | Pain | COMPLETED | NCT01367249 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT01367249 |
| Bromfenac Ophthalmic Solution | Other | Phase PHASE3 | Pain | COMPLETED | NCT01367249 |
| Atralin gel | Other | Phase PHASE3 | Rosacea | TERMINATED | NCT01125930 |
| vehicle gel | Other | Phase PHASE3 | Rosacea | TERMINATED | NCT01125930 |
| fluocinolone acetonide (Retisert Implant, Bausch and Lomb) | Other | Approved | Central Retinal Vein Occlusion | COMPLETED | NCT00952614 |
| Placebo | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT01090102 |
| Mesalamine (5-aminosalicylic acid, Apriso) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT01090102 |
| Gatifloxacin | Other | Phase PHASE3 | Bacterial Conjunctivitis | TERMINATED | NCT01330355 |
| Besivance | Other | Phase PHASE3 | Bacterial Conjunctivitis | TERMINATED | NCT01330355 |
| Vehicle of Zylet | Other | Phase PHASE4 | Conjunctivitis | COMPLETED | NCT00705159 |
| Tobramycin | Other | Phase PHASE4 | Conjunctivitis | COMPLETED | NCT00705159 |
| loteprednol etabonate | Other | Phase PHASE4 | Conjunctivitis | COMPLETED | NCT00705159 |
| loteprednol etabonate and tobramycin | Other | Phase PHASE4 | Conjunctivitis | COMPLETED | NCT00705159 |
| placebo | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00703781 |
| bromfenac ophthalmic solution | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00703781 |
| Vehicle of Ophthalmic Loteprednol Etabonate | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00699153 |
| Loteprednol Etabonate | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00699153 |
| Efudex (5-fluorouracil) | Other | Approved | Photo-aging | COMPLETED | NCT00121511 |
| IDP-121 Lotion | Other | Phase PHASE1 | Acne | COMPLETED | NCT02849860 |
| Thermage FLX | Other | Approved | Facial Skin Laxity | UNKNOWN | NCT03894371 |
| SP-333 | Other | Phase PHASE1 | Exposure | COMPLETED | NCT01705938 |
| DL6049 (injectable poly-L-lactic acid) | Other | Preclinical | Mid Facial Contour Deficiencies | COMPLETED | NCT00487474 |
| DL6049 (injectable poly-L-lactic acid) | Other | Phase PHASE3 | Nasolabial Fold Wrinkles | COMPLETED | NCT00444353 |
| DL6049 (injectable poly-L-lactic acid) | Other | Phase PHASE3 | Nasolabial Fold Wrinkles | COMPLETED | NCT00444210 |
| Luliconazole Cream 1% | Other | Phase PHASE4 | Tinea Pedis | COMPLETED | NCT02394340 |
| Omeprazole 40 mg | Other | Phase PHASE4 | Tinea Pedis | COMPLETED | NCT02394340 |
| Luliconazole Cream 1% | Other | Phase PHASE4 | Tinea Pedis | COMPLETED | NCT02394340 |
| Omeprazole 40 mg | Other | Phase PHASE4 | Tinea Pedis | COMPLETED | NCT02394340 |
| Healon® Viscoelastic (CONTROL) | Other | Approved | Cataract | COMPLETED | NCT02024711 |
| EYEFILL® C.-US Viscoelastic | Other | Approved | Cataract | COMPLETED | NCT02024711 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| orally disintegrating selegiline (Zelapar) | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00443872 |
| KeraSoft IC Soft Contact Lenses | Other | Approved | Keratoconus | TERMINATED | NCT01416272 |
| SoftPort LI61AO | Other | Phase PHASE4 | Cataract | TERMINATED | NCT01241279 |
| Crystalens AO | Other | Phase PHASE4 | Cataract | TERMINATED | NCT01241279 |
| B&L PureVision Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01449526 |
| B&L Investigational Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01449526 |
| Ketotifen/vasoconstrictor | Other | Phase PHASE2 | Allergic Conjunctivitis | WITHDRAWN | NCT00375596 |
| Ketotifen/vasoconstrictor | Other | Phase PHASE2 | Allergic Conjunctivitis | WITHDRAWN | NCT00375596 |
| Marketed 1 Day Contact Lens | Other | Approved | Myopia | COMPLETED | NCT00902850 |
| SofLens Daily Disposable | Other | Approved | Myopia | COMPLETED | NCT00902850 |
| Marketed 1 Day Contact Lens | Other | Approved | Myopia | COMPLETED | NCT00902850 |
| SofLens Daily Disposable | Other | Approved | Myopia | COMPLETED | NCT00902850 |
| SofLens59 contact lens | Other | Approved | Vision Disorders | COMPLETED | NCT00985231 |
| PureVision Multi-Focal contact lenses | Other | Approved | Vision Disorders | COMPLETED | NCT00985231 |
| SofLens59 contact lens | Other | Approved | Vision Disorders | COMPLETED | NCT00985231 |
| PureVision Multi-Focal contact lenses | Other | Approved | Vision Disorders | COMPLETED | NCT00985231 |
| Vehicle of Ophthalmic Loteprednol Etabonate | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00699153 |
| Loteprednol Etabonate | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00699153 |
| Vehicle of Loteprednol Etabonate Ophthalmic Ointment | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00645671 |
| 0.5% Loteprednol Etabonate Ophthalmic Ointment | Other | Phase PHASE3 | Ocular Inflammation | COMPLETED | NCT00645671 |
| Ciba Vision Aquify Multipurpose Solution | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Bausch & Lomb Multipurpose Solution - No Rub Care | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Bausch & Lomb Multipurpose Solution - Rub Care | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Ciba Vision Aquify Multipurpose Solution | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Bausch & Lomb Multipurpose Solution - No Rub Care | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Bausch & Lomb Multipurpose Solution - Rub Care | Other | Approved | Contact Lens Solutions | COMPLETED | NCT00636363 |
| Vehicle | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00622908 |
| ISV-403 | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00622908 |
| Vehicle | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00622908 |
| ISV-403 | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT00622908 |
| Moxifloxacin solution | Other | Phase PHASE3 | Acute Bacterial Conjunctivitis | COMPLETED | NCT00348348 |
| Besifloxacin | Other | Phase PHASE3 | Acute Bacterial Conjunctivitis | COMPLETED | NCT00348348 |
| Vehicle | Other | Phase PHASE3 | Acute Bacterial Conjunctivitis | COMPLETED | NCT00347932 |
| ISV-403 | Other | Phase PHASE3 | Acute Bacterial Conjunctivitis | COMPLETED | NCT00347932 |
| 0.59 mg Fluocinolone Acetonide implant | Other | Phase PHASE4 | Uveitis | COMPLETED | NCT00543296 |
| Rifaximin | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT00945334 |
| Placebo | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT00945334 |
| Neomycin | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT00945334 |
| Intraocular lens | Other | Phase PHASE4 | Glistenings | WITHDRAWN | NCT01131481 |
| Restasis | Other | Approved | Dry Eyes | COMPLETED | NCT01695668 |
| Lotemax | Other | Approved | Dry Eyes | COMPLETED | NCT01695668 |
| Rifaximin | Other | Phase PHASE4 | HIV | WITHDRAWN | NCT01654939 |
| Administration of Lotemax | Other | Approved | Sjogren's Disease | COMPLETED | NCT02322528 |
| Administration of Lotemax | Other | Approved | Sjogren's Disease | COMPLETED | NCT02322528 |
| Polytrim Treatment Group | Drug | Phase PHASE1 | Congenital Nasolacrimal Duct Obstruction | COMPLETED | NCT01431170 |
| Besivance Treatment Group | Drug | Phase PHASE1 | Congenital Nasolacrimal Duct Obstruction | COMPLETED | NCT01431170 |
| Brimonidine tartrate | Other | Phase PHASE1 | Hyperemia | COMPLETED | NCT02039765 |
| Sirdalud | Other | Phase PHASE3 | Vertebrogenic Radiculopathy L5, S1 | COMPLETED | NCT02508805 |
| Voltaren | Other | Phase PHASE3 | Vertebrogenic Radiculopathy L5, S1 | COMPLETED | NCT02508805 |
| Neuromultivit | Other | Phase PHASE3 | Vertebrogenic Radiculopathy L5, S1 | COMPLETED | NCT02508805 |
| Loteprednol Etabonate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03098953 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | TERMINATED | NCT02029495 |
| 140 mg brodalumab | Other | Phase PHASE3 | Psoriatic Arthritis | TERMINATED | NCT02029495 |
| 210 mg brodalumab | Other | Phase PHASE3 | Psoriatic Arthritis | TERMINATED | NCT02029495 |
| Tazorac Cream | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03058744 |
| Ultravate Cream | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03058744 |
| HP Monad Lotion | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03058744 |
| IDP-118 Lotion | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03058744 |
| Brodalumab | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02173392 |
| Verteporfin | Other | Approved | Neovascular Age-related Macular Degeneration | WITHDRAWN | NCT02457026 |
| Triamcinolone Acetonide | Other | Approved | Neovascular Age-related Macular Degeneration | WITHDRAWN | NCT02457026 |
| Aflibercept | Other | Approved | Neovascular Age-related Macular Degeneration | WITHDRAWN | NCT02457026 |
| Delayed-release omeprazole | Other | Phase PHASE4 | Gastroparesis | COMPLETED | NCT00492622 |
| Immediate-release omeprazole | Other | Phase PHASE4 | Gastroparesis | COMPLETED | NCT00492622 |
| B+L Advanced Eye Relief Lubricant Drop | Other | Phase PHASE4 | Meibomian Gland Dysfunction | COMPLETED | NCT01456780 |
| Loteprednol | Other | Phase PHASE4 | Meibomian Gland Dysfunction | COMPLETED | NCT01456780 |
| Loteprednol/tobramycin | Other | Phase PHASE4 | Meibomian Gland Dysfunction | COMPLETED | NCT01456780 |
| Rifaximin | Other | Approved | Hepatic Encephalopathy | TERMINATED | NCT01846806 |
| IDP-120 Gel | Other | Phase PHASE1 | Acne | COMPLETED | NCT02850003 |
| double-blind rifaximin | Other | Phase PHASE3 | Irritable Bowel Syndrome With Diarrhea | COMPLETED | NCT01543178 |
| double-blind placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome With Diarrhea | COMPLETED | NCT01543178 |
| open-label rifaximin | Other | Phase PHASE3 | Irritable Bowel Syndrome With Diarrhea | COMPLETED | NCT01543178 |
| Rifaximin | Other | Approved | Intestinal FDG Uptake | COMPLETED | NCT01542541 |
| IDP 120 Vehicle Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP 120 Component B Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP 120 Component A Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP-120 Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP 120 Vehicle Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP 120 Component B Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP 120 Component A Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| IDP-120 Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03003247 |
| Oral sodium phosphate solution | Other | Phase PHASE4 | Colon Cleansing | COMPLETED | NCT01427296 |
| Polyethylene glycol | Other | Phase PHASE4 | Colon Cleansing | COMPLETED | NCT01427296 |
| genteal gel | Other | Phase PHASE4 | Keratoconjunctivitis Due to Adenovirus | COMPLETED | NCT01533480 |
| Zirgan | Other | Phase PHASE4 | Keratoconjunctivitis Due to Adenovirus | COMPLETED | NCT01533480 |
| Methylnaltrexone bromide | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672139 |
| Methylnaltrexone bromide | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672139 |
| Placebo | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672477 |
| Methylnaltrexone | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672477 |
| Placebo | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672477 |
| Methylnaltrexone | Other | Phase PHASE4 | Opioid-Induced Constipation | COMPLETED | NCT00672477 |
| APRISO 375 mg extended-release capsules | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT03327558 |
| Apriso 0.375G ER CAP | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT03327558 |
| Latanoprostene bunod | Other | Phase PHASE1 | Intraocular Pressure | COMPLETED | NCT01895985 |
| Latanoprostene bunod | Other | Phase PHASE1 | Intraocular Pressure | COMPLETED | NCT01895985 |
| ACYC vehicle | Other | Phase PHASE3 | Acne | COMPLETED | NCT01701024 |
| ACYC | Other | Phase PHASE3 | Acne | COMPLETED | NCT01701024 |
| Tazorac Cream | Other | Phase PHASE1 | Acne | COMPLETED | NCT02849873 |
| IDP-123 Lotion | Other | Phase PHASE1 | Acne | COMPLETED | NCT02849873 |
| Latanoprost | Other | Phase PHASE2 | Intraocular Pressure | COMPLETED | NCT01223378 |
| BOL-303259-X | Other | Phase PHASE2 | Intraocular Pressure | COMPLETED | NCT01223378 |
| Latanoprost | Other | Phase PHASE2 | Intraocular Pressure | COMPLETED | NCT01223378 |
| BOL-303259-X | Other | Phase PHASE2 | Intraocular Pressure | COMPLETED | NCT01223378 |
| Standard MX60 plus corneal incisions | Other | Approved | Corneal Astigmatism | UNKNOWN | NCT03633851 |
| Toric intraocular MX60T lens | Other | Approved | Corneal Astigmatism | UNKNOWN | NCT03633851 |
| Timolol maleate | Other | Phase PHASE2 | Ocular Hypertension | COMPLETED | NCT01707381 |
| BOL-303259-X | Other | Phase PHASE2 | Ocular Hypertension | COMPLETED | NCT01707381 |
| Timolol | Other | Phase PHASE3 | Open-Angle Glaucoma | COMPLETED | NCT01749904 |
| BOL-303259-X | Other | Phase PHASE3 | Open-Angle Glaucoma | COMPLETED | NCT01749904 |
| Ilevro (nepafenac 0.3%) | Other | Approved | Cataract | COMPLETED | NCT01847638 |
| Prolensa (bromfenac 0.07%) | Other | Approved | Cataract | COMPLETED | NCT01847638 |
| 140 mg SC | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00867100 |
| Placebo | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00867100 |
| 350 mg SC | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00867100 |
| 700 mg IV | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00867100 |
| Single Vision Contact Lens | Other | Approved | Asthenopia | COMPLETED | NCT03544216 |
| Multifocal Contact Lens | Other | Approved | Asthenopia | COMPLETED | NCT03544216 |
| Nepafenac | Other | Phase PHASE4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | COMPLETED | NCT03886779 |
| Bromfenac | Other | Phase PHASE4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | COMPLETED | NCT03886779 |
| Nepafenac | Other | Phase PHASE4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | COMPLETED | NCT03886779 |
| Bromfenac | Other | Phase PHASE4 | Treatment of Ocular Inflammation Associated With Cataract Surgery | COMPLETED | NCT03886779 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02122471 |
| Plecanatide | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02122471 |
| Placebo | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01429987 |
| plecanatide | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01429987 |
| Prednisolones acetate | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01475643 |
| Loteprednol etabonate | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01475643 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT02493452 |
| Plecanatide | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT02493452 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT02387359 |
| Plecanatide | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT02387359 |
| Part 2 Group 4 | Other | Phase PHASE1 | Anaphylaxis | COMPLETED | NCT03282929 |
| Part 2 group 3 | Other | Phase PHASE1 | Anaphylaxis | COMPLETED | NCT03282929 |
| Part 2 group 2 | Other | Phase PHASE1 | Anaphylaxis | COMPLETED | NCT03282929 |
| Part 2 Group 1 | Other | Phase PHASE1 | Anaphylaxis | COMPLETED | NCT03282929 |
| Part 1 | Other | Phase PHASE1 | Anaphylaxis | COMPLETED | NCT03282929 |
| Fluocinolone Acetonide Intravitreal Implant | Other | Preclinical | Uveitis, Posterior | COMPLETED | NCT03145025 |
| Retisert | Other | Preclinical | Uveitis, Posterior | COMPLETED | NCT03145025 |
| Vehicle | Other | Phase PHASE2 | Vitreoretinal Traction Syndrome | TERMINATED | NCT00348439 |
| Plasmin | Other | Phase PHASE2 | Vitreoretinal Traction Syndrome | TERMINATED | NCT00348439 |
| Plasmin | Other | Phase PHASE1 | Vitreoretinal Traction Syndrome | TERMINATED | NCT00347646 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00975637 |
| 280 mg SC | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00975637 |
| 140 mg SC | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00975637 |
| 210 mg SC | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00975637 |
| 70 mg SC | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00975637 |
| Plecanatide | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01919697 |
| Silicone Hydrogel Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01873846 |
| AMG 827 | Other | Phase PHASE2 | Psoriasis | TERMINATED | NCT01101100 |
| AMG 827 | Other | Phase PHASE2 | Psoriasis | TERMINATED | NCT01101100 |
| Placebo | Other | Phase PHASE3 | Proctitis | COMPLETED | NCT01008423 |
| Budesonide | Other | Phase PHASE3 | Proctitis | COMPLETED | NCT01008423 |
| Rifaximin | Other | Phase PHASE3 | Hepatic Encephalopathy | COMPLETED | NCT00686920 |
| Balsalazide Disodium | Other | Phase PHASE3 | Inflammatory Bowel Disease | COMPLETED | NCT00486031 |
| Balsalazide Disodium | Other | Phase PHASE3 | Inflammatory Bowel Disease | COMPLETED | NCT00486031 |
| Daily disposable cosmetic tint lens | Other | Approved | Myopia | COMPLETED | NCT01230554 |
| Daily disposable cosmetic tint lens | Other | Approved | Myopia | COMPLETED | NCT01230554 |
| Soothe® Lubricant Eye Drops | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01817582 |
| Restasis | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01817582 |
| Lotemax | Other | Phase PHASE2 | Keratoconjunctivitis Sicca | COMPLETED | NCT01817582 |
| Methylnaltrexone | Other | Approved | Opioid-induced Constipation | COMPLETED | NCT01368562 |
| Placebo | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00528970 |
| MOA-728 | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00528970 |
| 5-ASA | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT01532648 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT01532648 |
| Budesonide MMX® | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT01532648 |
| Placebo | Other | Phase PHASE3 | Opioid-Induced Constipation | COMPLETED | NCT01186770 |
| Methylnaltrexone | Other | Phase PHASE3 | Opioid-Induced Constipation | COMPLETED | NCT01186770 |
| Placebo | Other | Phase PHASE3 | Opioid-Induced Constipation | COMPLETED | NCT01186770 |
| Methylnaltrexone | Other | Phase PHASE3 | Opioid-Induced Constipation | COMPLETED | NCT01186770 |
| Lactulose | Other | Phase PHASE4 | Hepatic Encephalopathy | COMPLETED | NCT01842581 |
| Rifaximin | Other | Phase PHASE4 | Hepatic Encephalopathy | COMPLETED | NCT01842581 |
| Lactulose | Other | Phase PHASE4 | Hepatic Encephalopathy | COMPLETED | NCT01842581 |
| Rifaximin | Other | Phase PHASE4 | Hepatic Encephalopathy | COMPLETED | NCT01842581 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Rifaximin EIR | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Rifaximin EIR | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Rifaximin EIR | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240121 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240108 |
| Rifaximin EIR | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240108 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240108 |
| Rifaximin EIR | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT02240108 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | TERMINATED | NCT00364689 |
| Lactulose | Other | Phase PHASE3 | Hepatic Encephalopathy | TERMINATED | NCT00364689 |
| Rifaximin | Other | Phase PHASE3 | Hepatic Encephalopathy | TERMINATED | NCT00364689 |
| DL6049 (injectable poly-L-lactic acid) | Other | Phase PHASE3 | Nasolabial Fold Wrinkles | COMPLETED | NCT00444210 |
| SCULPTRA (poly-L-lactic acid injection) | Other | Preclinical | Facial Lipoatrophy | COMPLETED | NCT00360932 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | COMPLETED | NCT00298038 |
| Rifaximin | Other | Phase PHASE3 | Hepatic Encephalopathy | COMPLETED | NCT00298038 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | COMPLETED | NCT00298038 |
| Rifaximin | Other | Phase PHASE3 | Hepatic Encephalopathy | COMPLETED | NCT00298038 |
| Matching placebo | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT03120520 |
| Plecanatide | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT03120520 |
| Vancomycin | Other | Phase PHASE3 | Clostridium Infections | COMPLETED | NCT00269399 |
| Rifaximin (Xifaxan) | Other | Phase PHASE3 | Clostridium Infections | COMPLETED | NCT00269399 |
| Vancomycin | Other | Phase PHASE3 | Clostridium Infections | COMPLETED | NCT00269399 |
| Rifaximin (Xifaxan) | Other | Phase PHASE3 | Clostridium Infections | COMPLETED | NCT00269399 |
| Vehicle control | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT01326780 |
| 3.6% JNJ 10229570-AAA | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT01326780 |
| 2.4% JNJ 10229570-AAA | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT01326780 |
| 1.2% JNJ 10229570-AAA | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT01326780 |
| N-methylnaltrexone bromide (MOA-728) | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00804141 |
| Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Sodium Fluorescein | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Vehicle | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Brimonidine Tartrate | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Sodium Fluorescein | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Vehicle | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Brimonidine Tartrate | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959243 |
| Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Sodium Fluorescein | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Vehicle | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Brimonidine Tartrate | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Sodium Fluorescein | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Vehicle | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Brimonidine Tartrate | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Sodium Fluorescein | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Vehicle | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Brimonidine Tartrate | Other | Phase PHASE3 | Hyperemia | COMPLETED | NCT01959230 |
| Bexarotene | Other | Phase PHASE4 | Refractory Cutaneous T-cell Lymphoma | COMPLETED | NCT01007448 |
| Trulign™ Toric IOL | Other | Preclinical | Cataract | COMPLETED | NCT02394379 |
| mesalamine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00622375 |
| Prednisolone Acetate 1% Oph Susp | Other | Phase PHASE4 | Conjunctivitis, Seasonal Allergic | COMPLETED | NCT01437982 |
| Loteprednol Etabonate | Other | Phase PHASE4 | Conjunctivitis, Seasonal Allergic | COMPLETED | NCT01437982 |
| Poly-L-Lactic Acid | Other | Phase PHASE4 | Skin Aging | COMPLETED | NCT00447551 |
| Poly-L-Lactic Acid Injection | Other | Approved | Healthy Volunteers | COMPLETED | NCT00869687 |
| Sculptra (Poly-L-Lactic Acid Dermal Implant) | Other | Approved | Acne Vulgaris | COMPLETED | NCT00795327 |
| Plecanatide | Other | Preclinical | Chronic Idiopathic Constipation | COMPLETED | NCT03551873 |
| placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00529087 |
| N-methylnaltrexone bromide (MOA-728) | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00529087 |
| placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00529087 |
| N-methylnaltrexone bromide (MOA-728) | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00529087 |
| MOA-728 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00464802 |
| crofelemer | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00461526 |
| MOA-728 | Other | Phase PHASE1 | Methadone-maintenance Subjects | COMPLETED | NCT00447811 |
| MOA-728 | Other | Phase PHASE1 | Constipation | COMPLETED | NCT00444158 |
| MOA-728 | Other | Phase PHASE1 | Constipation | COMPLETED | NCT00444158 |
| MOA-728 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00434395 |
| MOA-728 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00434395 |
| Balsalazide disodium | Other | Phase PHASE3 | Inflammatory Bowel Disease | COMPLETED | NCT00408174 |
| SC Placebo | Other | Phase PHASE3 | Advanced Illness Patients With Opioid Induced Constipation | COMPLETED | NCT00401362 |
| SC Methylnaltrexone | Other | Phase PHASE3 | Advanced Illness Patients With Opioid Induced Constipation | COMPLETED | NCT00401362 |
| SC Placebo | Other | Phase PHASE3 | Advanced Illness Patients With Opioid Induced Constipation | COMPLETED | NCT00401362 |
| SC Methylnaltrexone | Other | Phase PHASE3 | Advanced Illness Patients With Opioid Induced Constipation | COMPLETED | NCT00401362 |
| MOA-728 | Other | Phase PHASE1 | Metahdone-maintenance Subjects | COMPLETED | NCT00398502 |
| MOA-728 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00387985 |
| Methylnaltrexone (MOA-728) | Other | Phase PHASE3 | Post Operative Bowel Dysfunction | COMPLETED | NCT00387309 |
| MOA-728 | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00366431 |
| Rifaximin | Other | Phase PHASE3 | Diarrhea | COMPLETED | NCT00328380 |
| MOA-728 | Other | Phase PHASE1 | Postoperative Complications | COMPLETED | NCT00311350 |
| Rifaximin | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00269412 |
| Rifaximin | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00269412 |
| crofelemer | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00101725 |
| crofelemer | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00101725 |
| Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT00086541 |
| Ezetimibe | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02682680 |
| Colesevelam | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02682680 |
| Ezetimibe | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02682680 |
| Colesevelam | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02682680 |
| Vehicle Cream | Other | Phase PHASE4 | Tinea Corporis | COMPLETED | NCT02767947 |
| Luliconazole Cream 1% | Other | Phase PHASE4 | Tinea Corporis | COMPLETED | NCT02767947 |
| Luliconazole Cream 1% | Other | Phase PHASE4 | Tinea Pedis | COMPLETED | NCT02767271 |
| SC Methylnaltrexone | Other | Phase PHASE3 | Terminal Illness | COMPLETED | NCT01367613 |
| SC Methylnaltrexone | Other | Phase PHASE3 | Terminal Illness | COMPLETED | NCT01367613 |
| SC Methylnaltrexone (MNTX) | Other | Phase PHASE3 | Terminal Illness | COMPLETED | NCT01367600 |
| SC MNTX | Other | Phase PHASE2 | Bowel Dysfunction | COMPLETED | NCT01367574 |
| Placebo | Other | Phase PHASE2 | Postoperative Ileus | COMPLETED | NCT01367548 |
| IV Methylnaltrexone (MNTX) | Other | Phase PHASE2 | Postoperative Ileus | COMPLETED | NCT01367548 |
| Placebo | Other | Phase PHASE2 | Postoperative Ileus | COMPLETED | NCT01367548 |
| IV Methylnaltrexone (MNTX) | Other | Phase PHASE2 | Postoperative Ileus | COMPLETED | NCT01367548 |
| SC Placebo | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01367535 |
| Oral Paroxetine | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01367535 |
| IV Methylnaltrexone (MNTX) | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01367535 |
| SC Methylnaltrexone (MNTX) | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01367535 |
| Methylnaltrexone (MNTX) | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT01367509 |
| IV Methylnaltrexone (MNTX) | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01367496 |
| SC Methylnaltrexone (MNTX) | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01367496 |
| IV methylnaltrexone (MNTX) | Other | Phase PHASE1 | Healthy Male Volunteers | COMPLETED | NCT01367483 |
| methylnaltrexone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT01366378 |
| placebo | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01366365 |
| methylnaltrexone | Other | Phase PHASE1 | Healthy Adults | COMPLETED | NCT01366365 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00767728 |
| Granulated mesalamine | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00767728 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00744016 |
| Granulated mesalamine | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00744016 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00744016 |
| Granulated mesalamine | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00744016 |
| Methylnaltrexone bromide | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT01366326 |
| Placebo | Other | Phase PHASE2 | Tourette's Syndrome | WITHDRAWN | NCT01133353 |
| Tetrabenazine MR | Other | Phase PHASE2 | Tourette's Syndrome | WITHDRAWN | NCT01133353 |
| placebo | Other | Phase PHASE4 | Opioid-Induced Constipation | WITHDRAWN | NCT00858754 |
| methylnaltrexone | Other | Phase PHASE4 | Opioid-Induced Constipation | WITHDRAWN | NCT00858754 |
| placebo | Other | Phase PHASE4 | Opioid-Induced Constipation | WITHDRAWN | NCT00858754 |
| methylnaltrexone | Other | Phase PHASE4 | Opioid-Induced Constipation | WITHDRAWN | NCT00858754 |
| rifaximin | Other | Phase PHASE1 | Pharmacokinetic | COMPLETED | NCT00743912 |
| Placebo | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00731679 |
| Rifaximin | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00731679 |
| Placebo | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00731679 |
| Rifaximin | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00731679 |
| Placebo | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00724126 |
| Rifaximin | Other | Phase PHASE3 | Non-Constipation Irritable Bowel Syndrome | COMPLETED | NCT00724126 |
| MOA-728 | Other | Phase PHASE1 | Methadone-maintenance Subjects | WITHDRAWN | NCT00505583 |
| MOA-728 | Other | Phase PHASE1 | Methadone-maintenance Subjects | WITHDRAWN | NCT00505583 |
| adefovir dipivoxyl | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT00230490 |
| pradefovir mesylate | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT00230490 |
| Asacol® 400 mg | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00679432 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00679432 |
| budesonide-MMX® 9 mg | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00679432 |
| budesonide-MMX® 6 mg | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00679432 |
| Blood sampling, endoscopy | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00679432 |
| IDP-121 Vehicle Lotion | Other | Phase PHASE3 | Acne | COMPLETED | NCT02965456 |
| IDP 121 Lotion | Other | Phase PHASE3 | Acne | COMPLETED | NCT02965456 |
| Bausch + Lomb Pure Vision Soft Contact Lens | Other | Approved | Myopia | COMPLETED | NCT02939950 |
| Bausch + Lomb Samfilcon A Soft Contact Lens | Other | Approved | Myopia | COMPLETED | NCT02939950 |
| Bisacodyl | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01982240 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01982240 |
| Plecanatide | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01982240 |
| Placebo | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01053962 |
| SP-304 9.0 mg | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01053962 |
| SP-304 3.0 mg | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01053962 |
| SP-304 1.0 mg | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01053962 |
| SP-304 0.3 mg | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01053962 |
| Ribavirin (Virazole) Injection | Other | Phase PHASE2 | Crimean-Congo Hemorrhagic Fever | WITHDRAWN | NCT00992693 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00936884 |
| Methylnaltrexone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00936884 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00936884 |
| Methylnaltrexone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT00936884 |
| placebo | Other | Phase PHASE3 | Plaque Psoriasis | TERMINATED | NCT01708629 |
| ustekinumab | Other | Phase PHASE3 | Plaque Psoriasis | TERMINATED | NCT01708629 |
| 140 mg brodalumab | Other | Phase PHASE3 | Plaque Psoriasis | TERMINATED | NCT01708629 |
| 210 mg brodalumab | Other | Phase PHASE3 | Plaque Psoriasis | TERMINATED | NCT01708629 |
| placebo | Other | Phase PHASE3 | Psoriasis | TERMINATED | NCT01708590 |
| 140 mg brodalumab | Other | Phase PHASE3 | Psoriasis | TERMINATED | NCT01708590 |
| 210 mg brodalumab | Other | Phase PHASE3 | Psoriasis | TERMINATED | NCT01708590 |
| placebo | Other | Phase PHASE3 | Moderate to Severe Plaque Psoriasis | TERMINATED | NCT01708603 |
| ustekinumab | Other | Phase PHASE3 | Moderate to Severe Plaque Psoriasis | TERMINATED | NCT01708603 |
| 140 mg brodalumab | Other | Phase PHASE3 | Moderate to Severe Plaque Psoriasis | TERMINATED | NCT01708603 |
| 210 mg brodalumab | Other | Phase PHASE3 | Moderate to Severe Plaque Psoriasis | TERMINATED | NCT01708603 |
| Non-Contact Lens Wear | Other | Preclinical | Dry Eye | TERMINATED | NCT01317030 |
| Contact Lens Wear | Other | Preclinical | Dry Eye | TERMINATED | NCT01317030 |
| IDP-118 Lotion | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02462083 |
| corneas assigned by donor age group | Other | Approved | Corneal Disease | COMPLETED | NCT00006411 |
| Zen™ RC | Other | Approved | Keratoconus | UNKNOWN | NCT03249233 |
| ZenLens™ | Other | Approved | Keratoconus | UNKNOWN | NCT03249233 |
| Zen™ RC | Other | Approved | Keratoconus | UNKNOWN | NCT03249233 |
| ZenLens™ | Other | Approved | Keratoconus | UNKNOWN | NCT03249233 |
| Once a day Trientine | Other | Approved | Wilson Disease | COMPLETED | NCT01472874 |
| Salix Probiotic Blend | Other | Approved | Functional Gastrointestinal Disorders | COMPLETED | NCT04155801 |
| Plecanatide | Other | Phase PHASE3 | Irritable Bowel Syndrome | COMPLETED | NCT02706483 |
| Ultravate Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785172 |
| IDP-118 Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785172 |
| IDP-118 Vehicle Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785172 |
| IDP-118 Vehicle Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785172 |
| IDP-118 Vehicle Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Vehicle Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| Tazorac Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Vehicle Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Vehicle Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| Tazorac Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785159 |
| IDP-118 Vehicle Lotion | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02462122 |
| IDP-118 Lotion | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02462122 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02024646 |
| 140 mg brodalumab | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02024646 |
| 210 mg brodalumab | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02024646 |
| Placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00605644 |
| MOA-728 | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00605644 |
| placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00547586 |
| N-methylnaltrexone bromide (MOA-728) | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00547586 |
| placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00547586 |
| N-methylnaltrexone bromide (MOA-728) | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00547586 |
| Ultravate Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785185 |
| IDP-122 Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785185 |
| IDP-122 Vehicle Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785185 |
| IDP-122 Vehicle Lotion | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02785185 |
| AMG 827 210 | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT01516957 |
| AMG 827 280 | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT01516957 |
| Placebo | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT01516957 |
| AMG 827 140 | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT01516957 |
| Crofelemer | Other | Phase PHASE3 | HIV Enteropathy | COMPLETED | NCT01374490 |
| Vehicle | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01591655 |
| Mapracorat | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01591655 |
| Placebo | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01591161 |
| Mapracorat | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01591161 |
| Vehicle | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01230125 |
| Mapracorat | Other | Phase PHASE3 | Cataract | COMPLETED | NCT01230125 |
| placebo | Other | Phase PHASE2 | Dry Eye Disease | COMPLETED | NCT00667004 |
| ecabet ophthalmic solution | Other | Phase PHASE2 | Dry Eye Disease | COMPLETED | NCT00667004 |
| placebo | Other | Phase PHASE2 | Dry Eye Disease | COMPLETED | NCT00667004 |
| ecabet ophthalmic solution | Other | Phase PHASE2 | Dry Eye Disease | COMPLETED | NCT00667004 |
| Placebo | Other | Phase PHASE3 | HIV Associated Diarrhea | COMPLETED | NCT00547898 |
| Crofelemer 500 mg | Other | Phase PHASE3 | HIV Associated Diarrhea | COMPLETED | NCT00547898 |
| Crofelemer 250 mg | Other | Phase PHASE3 | HIV Associated Diarrhea | COMPLETED | NCT00547898 |
| Crofelemer 125 mg | Other | Phase PHASE3 | HIV Associated Diarrhea | COMPLETED | NCT00547898 |
| lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT03122457 |
| lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT03122457 |
| Vehicle | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT01289431 |
| Mapracorat | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT01289431 |
| Vehicle | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT01289431 |
| Mapracorat | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT01289431 |
| Bausch & Lomb 217z Excimer Laser | Other | Approved | Myopia | COMPLETED | NCT00769808 |
| B&L Investigational Contact Lens | Other | Approved | Corneal Deformity | COMPLETED | NCT02258139 |
| placebo comparator ophthalmic solution | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01174823 |
| bepotastine besilate ophthalmic solution | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01174823 |
| placebo comparator ophthalmic solution | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01174823 |
| bepotastine besilate ophthalmic solution | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT01174823 |
| bromfenac ophthalmic solution 0.06% | Other | Phase PHASE2 | Dry Eye Disease | COMPLETED | NCT00758784 |
| Latanoprost Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00595101 |
| PF-03187207 Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00595101 |
| Latanoprost 0.005% | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00595101 |
| PF-03187207 | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00595101 |
| Latanoprost 0.005% and PF-03187207 Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00441883 |
| PF-03187207 and Latanoprost Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00441883 |
| Latanoprost 0.005% and PF-03187207 Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00441883 |
| PF-03187207 and Latanoprost Vehicle | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT00441883 |
| Technolas 217z Zyoptix Laser | Other | Approved | Hyperopia | COMPLETED | NCT00348205 |
| Vehicle for BOL-303242-X | Other | Phase PHASE2 | Cataract | COMPLETED | NCT00905450 |
| BOL-303242-X | Other | Phase PHASE2 | Cataract | COMPLETED | NCT00905450 |
| Vehicle Cream | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02938494 |
| Vehicle Lotion | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02938494 |
| Tazorac Cream | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02938494 |
| IDP-123 Lotion | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02938494 |
| Vehicle Gel (BID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT02208297 |
| Loteprednol Etabonate Gel (BID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT02208297 |
| Vehicle (TID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01996839 |
| Vehicle (BID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01996839 |
| Loteprednol Etabonate Gel (TID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01996839 |
| Loteprednol Etabonate Gel (BID) | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT01996839 |
| Pred Forte | Other | Phase PHASE2 | Cataract | COMPLETED | NCT00699803 |
| T-PRED | Other | Phase PHASE2 | Cataract | COMPLETED | NCT00699803 |
| Air Optix Aqua MF | Other | Approved | Presbyopia | COMPLETED | NCT01959178 |
| LD127025 MF | Other | Approved | Presbyopia | COMPLETED | NCT01959178 |
| PureVision multifocal contact lens | Other | Approved | Presbyopia | COMPLETED | NCT01539694 |
| LD118033 contact lens | Other | Approved | Presbyopia | COMPLETED | NCT01539694 |
| PureVision contact lens | Other | Approved | Presbyopia | COMPLETED | NCT01518868 |
| Investigational contact lens | Other | Approved | Presbyopia | COMPLETED | NCT01518868 |
| Placebo | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01753739 |
| Bepotastine besilate | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01753739 |
| Placebo | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01753739 |
| Bepotastine besilate | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01753739 |
| Placebo Nasal Spray | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01277341 |
| Bepotastine Besilate Nasal Spray 4% Twice a day | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01277341 |
| Bepotastine Besilate Nasal Spray 3% Twice a day | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01277341 |
| Bepotastine Besilate Nasal Spray 2% Twice a day | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT01277341 |
| placebo comparator nasal product | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01222299 |
| bepotastine besilate nasal product - high dose | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01222299 |
| bepotastine besilate nasal product - medium dose | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01222299 |
| bepotastine besilate nasal product - low dose | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01222299 |
| Vehicle | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT01159015 |
| KetoNaph | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT01159015 |
| PureVision Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01118338 |
| Redesigned Purevision Contact Lens | Other | Approved | Myopia | COMPLETED | NCT01118338 |
| Johnson and Johnson 1-Day Acuvue Moist contact lenses | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Bausch & Lomb SofLens daily disposable contact lenses. | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Novel Bausch & Lomb daily disposable contact lenses | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Johnson and Johnson 1-Day Acuvue Moist contact lenses | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Bausch & Lomb SofLens daily disposable contact lenses. | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Novel Bausch & Lomb daily disposable contact lenses | Other | Approved | Myopia | COMPLETED | NCT00784641 |
| Clear Care Solution | Other | Approved | Vision Disorders | COMPLETED | NCT01318577 |
| Investigational Cleaning & Disinfecting Solution | Other | Approved | Vision Disorders | COMPLETED | NCT01318577 |
| Clear Care Solution | Other | Approved | Vision Disorders | COMPLETED | NCT01318577 |
| Investigational Cleaning & Disinfecting Solution | Other | Approved | Vision Disorders | COMPLETED | NCT01318577 |
| PureVision Toric Lens | Other | Approved | Myopia | COMPLETED | NCT01309867 |
| Investigational Toric Lens | Other | Approved | Myopia | COMPLETED | NCT01309867 |
| PureVision Toric Lens | Other | Approved | Myopia | COMPLETED | NCT01309867 |
| Investigational Toric Lens | Other | Approved | Myopia | COMPLETED | NCT01309867 |
| Pred Forte | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00854061 |
| T-Pred | Other | Phase PHASE3 | Cataract | COMPLETED | NCT00854061 |
| Air Optix Aqua | Other | Approved | Myopia | COMPLETED | NCT01583868 |
| PureVision2 | Other | Approved | Myopia | COMPLETED | NCT01583868 |
| B&L RD2135-01 lens D | Other | Approved | Myopia | COMPLETED | NCT01583868 |
| B&L RD2135-01 lens C | Other | Approved | Myopia | COMPLETED | NCT01583868 |
| Vehicle | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00770133 |
| Ketotifen | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00770133 |
| Naphazoline | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00770133 |
| Ketotifen/naphazoline | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00770133 |
| Biotrue ONEday Daily Disposable Contact Lenses | Other | Approved | Contact Lens Wear | COMPLETED | NCT04158466 |
| Kalifilcon A Daily Disposable Contact Lenses | Other | Approved | Contact Lens Wear | COMPLETED | NCT04158466 |
| placebo | Other | Approved | Hepatic Encephalopathy | COMPLETED | NCT00533910 |
| Rifaximin | Other | Approved | Hepatic Encephalopathy | COMPLETED | NCT00533910 |
| placebo | Other | Approved | Hepatic Encephalopathy | COMPLETED | NCT00533910 |
| Rifaximin | Other | Approved | Hepatic Encephalopathy | COMPLETED | NCT00533910 |
| Test | Other | Approved | Astigmatism | COMPLETED | NCT03681808 |
| Control | Other | Approved | Astigmatism | COMPLETED | NCT03681808 |
| Samfilcon A | Other | Approved | Myopia | COMPLETED | NCT03351101 |
| Senofilcon C | Other | Approved | Myopia | COMPLETED | NCT03351101 |
| Samfilcon A | Other | Approved | Myopia | COMPLETED | NCT03351101 |
| Senofilcon C | Other | Approved | Myopia | COMPLETED | NCT03351101 |
| Vehicle Gel | Other | Phase PHASE3 | Cataract | COMPLETED | NCT02786901 |
| Loteprednol Etabonate Ophthalmic Gel dosed BID | Other | Phase PHASE3 | Cataract | COMPLETED | NCT02786901 |
| Loteprednol Etabonate Ophthalmic Gel dosed TID | Other | Phase PHASE3 | Cataract | COMPLETED | NCT02786901 |
| pegaptanib sodium injection | Other | Phase PHASE4 | Age-Related Macular Degeneration | COMPLETED | NCT01573572 |
| Imiquimod 3.75% Cream | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT03914417 |
| Imiquimod 3.75% Cream | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT03914417 |
| Placebo | Other | Approved | Liver Cirrhosis | TERMINATED | NCT01951209 |
| Rifaximin | Other | Approved | Liver Cirrhosis | TERMINATED | NCT01951209 |
| IDP-123 Vehicle Lotion | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03168334 |
| IDP-123 Lotion | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03168334 |
| IDP-123 Vehicle Lotion | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03168321 |
| IDP-123 Lotion | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03168321 |
| Vehicle | Other | Phase PHASE4 | Photodamaged Skin | UNKNOWN | NCT04096742 |
| tretinoin 0.05% lotion (Altreno) | Other | Phase PHASE4 | Photodamaged Skin | UNKNOWN | NCT04096742 |
| 0.1% Fluocinonide Cream | Other | Approved | Mycosis Fungoides | WITHDRAWN | NCT02301494 |
| 3.75% Imiquimod Cream | Other | Approved | Mycosis Fungoides | WITHDRAWN | NCT02301494 |
| Placebo | Other | Phase PHASE2 | Pancreatic Cancer | WITHDRAWN | NCT04083651 |
| Methylnaltrexone bromide | Other | Phase PHASE2 | Pancreatic Cancer | WITHDRAWN | NCT04083651 |
| Placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT01983306 |
| SP-333 6 mg | Other | Phase PHASE2 | Constipation | COMPLETED | NCT01983306 |
| SP-333 3 mg | Other | Phase PHASE2 | Constipation | COMPLETED | NCT01983306 |
| SP-333 1 mg | Other | Phase PHASE2 | Constipation | COMPLETED | NCT01983306 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04529811 |
| Rifaximin Novel Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04529811 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| SAN-300 4.0 mg/kg QW | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| SAN-300 4.0 mg/kg QOW | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| SAN-300 2.0 mg/kg QOW | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| SAN-300 1.0 mg/kg QW | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| SAN-300 0.5 mg/kg QW | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02047604 |
| senofilcon A | Other | Approved | Myopia | COMPLETED | NCT04901897 |
| delefilcon A | Other | Approved | Myopia | COMPLETED | NCT04901897 |
| kalifilcon A | Other | Approved | Myopia | COMPLETED | NCT04901897 |
| Precision1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Dailies Total1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Kalifon A | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Precision1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Dailies Total1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Kalifon A | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04840563 |
| Thermage FLX | Other | Approved | Skin Wrinkling | COMPLETED | NCT04606368 |
| Fluconazole | Other | Phase PHASE2 | Cryptococcal Infection Disseminated | TERMINATED | NCT01562132 |
| Flucytosine and fluconazole | Other | Phase PHASE2 | Cryptococcal Infection Disseminated | TERMINATED | NCT01562132 |
| Efinaconazole | Other | Phase PHASE4 | Onychomycosis | COMPLETED | NCT02812771 |
| Biotrue ONEday | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| Precision 1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| Dalies Total 1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| kalifilcon A lenses | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| Biotrue ONEday | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| Precision 1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| Dalies Total 1 | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| kalifilcon A lenses | Other | Approved | Habitual Soft Contact Lens Use | COMPLETED | NCT04555031 |
| No Intervention | Other | Preclinical | Neovascular Age-related Macular Degeneration | COMPLETED | NCT02452840 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05229510 |
| 100 mg/mL Virazole Inhalant Product | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05229510 |
| 50 mg/mL Virazole Inhalant Product | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05229510 |
| samfilcon A for Presbyopia | Other | Approved | Presbyopia | COMPLETED | NCT05325931 |
| kalifilcon A Daily Disposable Multifocal | Other | Approved | Presbyopia | COMPLETED | NCT05325931 |
| Placebo | Other | Approved | Celiac Disease | COMPLETED | NCT01137955 |
| Rifaximin | Other | Approved | Celiac Disease | COMPLETED | NCT01137955 |
| Brodalumab | Other | Preclinical | Psoriasis | COMPLETED | NCT04149587 |
| Brodalumab | Other | Preclinical | Psoriasis | COMPLETED | NCT04149587 |
| Rifaximin | Other | Phase PHASE2 | Visceral Hypersensitivity | TERMINATED | NCT03462966 |
| Rifaximin | Other | Phase PHASE2 | Visceral Hypersensitivity | TERMINATED | NCT03462966 |
| Standard Photorefractive keratectomy (PRK) | Other | Approved | Ametropia | COMPLETED | NCT04698174 |
| Transepithelial Photorefractive keratectomy (tPRK) with laser polishing | Other | Approved | Ametropia | COMPLETED | NCT04698174 |
| Transepithelial Photorefractive keratectomy (tPRK) without laser polishing | Other | Approved | Ametropia | COMPLETED | NCT04698174 |
| Ultra for Astigmatism Contact Lenses | Other | Approved | Myopia | COMPLETED | NCT05320042 |
| kalifilcon A Daily Disposable Toric | Other | Approved | Myopia | COMPLETED | NCT05320042 |
| OcuFresh Eye Wash | Other | Phase EARLY_PHASE1 | Dry Eye | COMPLETED | NCT01375582 |
| Liposic EDO | Other | Phase EARLY_PHASE1 | Dry Eye | COMPLETED | NCT01375582 |
| B & L Soothe Lubricant Eye Drops | Other | Phase EARLY_PHASE1 | Dry Eye | COMPLETED | NCT01375582 |
| CATARACT SURGERY | Procedure | Preclinical | Astigmatism | COMPLETED | NCT05739656 |
| Sensitive Eyes® Rewetting Drops | Other | Approved | Contact Lens Wear | COMPLETED | NCT03897751 |
| COMPLETE Multi-Purpose Solution | Other | Approved | Contact Lens Wear | COMPLETED | NCT03897751 |
| ABT12 Multi-Purpose Solution | Other | Approved | Contact Lens Wear | COMPLETED | NCT03897751 |
| IDp-120 Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03664739 |
| IDP-120 Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03664739 |
| IDp-120 Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03664739 |
| IDP-120 Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03664739 |
| Placebo | Other | Phase PHASE2 | Overt Hepatic Encephalopathy | COMPLETED | NCT03515044 |
| 80 mg Rifaximin SSD twice daily | Other | Phase PHASE2 | Overt Hepatic Encephalopathy | COMPLETED | NCT03515044 |
| 80 mg Rifaximin SSD once daily | Other | Phase PHASE2 | Overt Hepatic Encephalopathy | COMPLETED | NCT03515044 |
| 40 mg Rifaximin SSD twice daily | Other | Phase PHASE2 | Overt Hepatic Encephalopathy | COMPLETED | NCT03515044 |
| 40 mg Rifaximin SSD once daily | Other | Phase PHASE2 | Overt Hepatic Encephalopathy | COMPLETED | NCT03515044 |
| IDP-124 Vehicle Lotion | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03058783 |
| IDP-124 Lotion | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03058783 |
| IDP-124 Vehicle Lotion | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03002571 |
| IDP-124 Lotion | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03002571 |
| Azopt 1% | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT03896633 |
| brinzolamide 1% ophthalmic suspension | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT03896633 |
| Azopt 1% | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT03896633 |
| brinzolamide 1% ophthalmic suspension | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT03896633 |
| Azopt 1% | Other | Phase PHASE3 | Glaucoma | COMPLETED | NCT01722604 |
| brinzolamide 1% ophthalmic suspension | Other | Phase PHASE3 | Glaucoma | COMPLETED | NCT01722604 |
| Vehicle | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03489941 |
| Zaditor® | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03489941 |
| EM-100 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03489941 |
| Placebo | Other | Phase PHASE4 | Obesity | UNKNOWN | NCT04589130 |
| Contrave 8Mg-90Mg Extended-Release Tablet | Other | Phase PHASE4 | Obesity | UNKNOWN | NCT04589130 |
| Placebo | Other | Phase PHASE4 | Obesity | UNKNOWN | NCT04587843 |
| Contrave 8Mg-90Mg Extended-Release Tablet | Other | Phase PHASE4 | Obesity | UNKNOWN | NCT04587843 |
| Timolol maleate 0.5% BID | Other | Approved | OAG - Open-Angle Glaucoma | COMPLETED | NCT03931317 |
| Latanoprostene bunod 0.024% QD | Other | Approved | OAG - Open-Angle Glaucoma | COMPLETED | NCT03931317 |
| Duobrii® | Other | Phase PHASE4 | Palmoplantar Psoriasis | COMPLETED | NCT04720105 |
| CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. | Other | Approved | Photoaging | COMPLETED | NCT05027282 |
| CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. | Other | Approved | Photoaging | COMPLETED | NCT05027282 |
| REVIVE Contact Lens | Other | Approved | Refractive Ametropia | COMPLETED | NCT06053736 |
| Rifaximin | Other | Phase PHASE4 | Hepatic Encephalopathy | TERMINATED | NCT01846663 |
| Placebo | Other | Phase PHASE4 | Hepatic Encephalopathy | TERMINATED | NCT01846663 |
| IDP-126 Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214652 |
| IDP-126 Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214652 |
| IDP-126 Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214639 |
| IDP-126 Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214639 |
| IDP-126 Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214639 |
| IDP-126 Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT04214639 |
| Placebo | Other | Phase PHASE4 | Ocular Hypertension | WITHDRAWN | NCT04140279 |
| Latanoprostene Bunod | Other | Phase PHASE4 | Ocular Hypertension | WITHDRAWN | NCT04140279 |
| NOV03 | Other | Phase PHASE3 | Dry Eye Disease (DED) | COMPLETED | NCT04140227 |
| enVista non-Toric (spherical) | Other | Preclinical | Corneal Astigmatism | COMPLETED | NCT05075746 |
| enVista Toric | Other | Preclinical | Corneal Astigmatism | COMPLETED | NCT05075746 |
| Vehicle | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00769886 |
| Naphazoline | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00769886 |
| Ketotifen | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00769886 |
| Ketotifen/naphazoline | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT00769886 |
| new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens | Other | Approved | Myopia and Hyperopia and Presbyopia | COMPLETED | NCT05660577 |
| Cataract Surgery | Procedure | Approved | Cataract | COMPLETED | NCT04192630 |
| ProVisc OVD | Other | Approved | Cataract | COMPLETED | NCT04192630 |
| CVisc50 OVD | Other | Approved | Cataract | COMPLETED | NCT04192630 |
| Technolas® TENEO 317 Model 2 | Other | Approved | Myopia | COMPLETED | NCT04111757 |
| Technolas® TENEO 317 Model 2 | Other | Approved | Myopia | COMPLETED | NCT04111757 |
| OPTI-FREE | Other | Approved | Contact Lens Wear | COMPLETED | NCT04175340 |
| BL-300-PFM04 | Other | Approved | Contact Lens Wear | COMPLETED | NCT04175340 |
| Intraocular lens implantation | Other | Approved | Congenital Cataract | COMPLETED | NCT00212134 |
| Contact lens correction of aphakia | Other | Approved | Congenital Cataract | COMPLETED | NCT00212134 |
| Saline Solution | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04567329 |
| NOV03 | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04567329 |
| Lumify® (brimonidine tartrate ophthalmic solution 0.025%) | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT05360784 |
| Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT05360784 |
| Systane | Other | Approved | Dry Eye Disease | COMPLETED | NCT01650584 |
| ISTA Tears | Other | Approved | Dry Eye Disease | COMPLETED | NCT01650584 |
| Systane | Other | Approved | Dry Eye Disease | COMPLETED | NCT01650584 |
| ISTA Tears | Other | Approved | Dry Eye Disease | COMPLETED | NCT01650584 |
| Placebo | Other | Phase PHASE3 | Dry Eye Disease (DED) | COMPLETED | NCT04139798 |
| NOV03 | Other | Phase PHASE3 | Dry Eye Disease (DED) | COMPLETED | NCT04139798 |
| MyDay Toric | Other | Approved | Astigmatism | COMPLETED | NCT06098937 |
| Precision1 for Astigmatism | Other | Approved | Astigmatism | COMPLETED | NCT06098937 |
| Total1 for Astigmatism | Other | Approved | Astigmatism | COMPLETED | NCT06098937 |
| Kalifilcon Toric Lens | Other | Approved | Astigmatism | COMPLETED | NCT06098937 |
| Saline | Other | Phase PHASE4 | Dry Eye | ACTIVE_NOT_RECRUITING | NCT06565650 |
| Miebo | Other | Phase PHASE4 | Dry Eye | ACTIVE_NOT_RECRUITING | NCT06565650 |
| enVista MX60EF | Other | Approved | Cataract | COMPLETED | NCT03603600 |
| enVista MX60E | Other | Approved | Cataract | COMPLETED | NCT03603600 |
| minocycline HCl microspheres | Other | Phase PHASE4 | SRP | COMPLETED | NCT03762915 |
| Vehicle | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05579730 |
| Ketotifen Fumarate 0.035% | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05579730 |
| Brimonidine Tartrate 0.025% | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05579730 |
| Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05579730 |
| Placebo | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Larsucosterol | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Active Comparator: Single vision soft lens design (SVSL | Other | Approved | Nearsightedness | ACTIVE_NOT_RECRUITING | NCT06527274 |
| Experimental: Myopic defocus soft lens design (MDSL) | Other | Approved | Nearsightedness | ACTIVE_NOT_RECRUITING | NCT06527274 |
| Timolol 0.5% | Other | Phase PHASE1 | Glaucoma, Primary Open Angle | COMPLETED | NCT04149899 |
| WB007 0.4% | Other | Phase PHASE1 | Glaucoma, Primary Open Angle | COMPLETED | NCT04149899 |
| WB007 0.15% | Other | Phase PHASE1 | Glaucoma, Primary Open Angle | COMPLETED | NCT04149899 |
| WB007 0.05% | Other | Phase PHASE1 | Glaucoma, Primary Open Angle | COMPLETED | NCT04149899 |
| Miebo | Other | Phase PHASE4 | Dry Eye | COMPLETED | NCT06346340 |
| enVista Aspire EA IOLs | Other | Preclinical | Cataract | COMPLETED | NCT06333028 |
| enVista Aspire EA IOLs | Other | Preclinical | Cataract | COMPLETED | NCT06333028 |
| CT scan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Brodalumab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06673329 |
| Vismed Multi eye drops | Other | Approved | Dry Eye | COMPLETED | NCT03368404 |
| CBL-102 eye drops | Other | Approved | Dry Eye | COMPLETED | NCT03368404 |
| renu® Advanced Formula multi-purpose solution | Other | Approved | Refractive Ametropia | COMPLETED | NCT05565937 |
| BL-3100-NBR03 multi-purpose solution | Other | Approved | Refractive Ametropia | COMPLETED | NCT05565937 |
| TENEO 317 Model 2 excimer laser | Other | Approved | Myopia | NOT_YET_RECRUITING | NCT06618547 |
| Acuvue Oasys 1-Day for Astigmatism | Other | Approved | Astigmatism | COMPLETED | NCT06069609 |
| kalifilcon A Daily Disposable Toric | Other | Approved | Astigmatism | COMPLETED | NCT06069609 |
| Experimental: Vehicle ophthalmic solution | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Brimonidine tartrate ophthalmic solution 0.025% | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Ketotifen fumarate ophthalmic solution 0.035% | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Experimental: Vehicle ophthalmic solution | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Brimonidine tartrate ophthalmic solution 0.025% | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Ketotifen fumarate ophthalmic solution 0.035% | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Other | Phase PHASE3 | Seasonal Allergic Conjunctivitis | COMPLETED | NCT05591755 |
| instillation of NOV03 | Other | Phase PHASE4 | Dry Eye Disease (DED) | COMPLETED | NCT05723770 |
| instillation of NOV03 | Other | Phase PHASE4 | Dry Eye Disease (DED) | COMPLETED | NCT05723770 |
| Lumify® | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT06803654 |
| BTOS-HA | Other | Phase PHASE3 | Ocular Redness | COMPLETED | NCT06803654 |
| enVista Aspire EA or Aspire Toric ETA IOLs | Other | Approved | Cataract | COMPLETED | NCT06594185 |
| Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05815758 |
| Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05815758 |
| Commercially available Ultra for Astigmatism Contact Lenses | Other | Approved | Astigmatism | COMPLETED | NCT05129124 |
| kalifilcon A Daily Disposable Toric LD213001 Contact Lenses | Other | Approved | Astigmatism | COMPLETED | NCT05129124 |
| Commercially Available B+L Ultra Lenses | Other | Approved | Contact Lens Wearer | COMPLETED | NCT05126953 |
| samfilcon A Lenses with EPG01 Packaging Solution | Other | Approved | Contact Lens Wearer | COMPLETED | NCT05126953 |
| Commercially Available B+L Ultra Lenses | Other | Approved | Contact Lens Wearer | COMPLETED | NCT05126953 |
| samfilcon A Lenses with EPG01 Packaging Solution | Other | Approved | Contact Lens Wearer | COMPLETED | NCT05126953 |
| Scaling and Root Planing (SRP) | Other | Approved | Periodontitis | ACTIVE_NOT_RECRUITING | NCT05422742 |
| SRP + MM | Other | Approved | Periodontitis | ACTIVE_NOT_RECRUITING | NCT05422742 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05071716 |
| Rifaximin SSD | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05071716 |
| Propylene Glycol Preservative-free Artificial Tears | Other | Phase PHASE4 | Vein Occlusion | COMPLETED | NCT07090044 |
| Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly | Other | Phase PHASE4 | Vein Occlusion | COMPLETED | NCT07090044 |
| Bromfenac Sodium 0.07% | Other | Phase PHASE4 | Vein Occlusion | COMPLETED | NCT07090044 |
| Placebo | Other | Phase PHASE4 | Obesity; Drug | RECRUITING | NCT06620562 |
| Naltrexone/Bupropion | Other | Phase PHASE4 | Obesity; Drug | RECRUITING | NCT06620562 |
| orthokeratology lens | Other | Approved | Myopia | COMPLETED | NCT05984290 |
| IDP-122 Lotion | Other | Phase PHASE4 | Psoriasis | RECRUITING | NCT03987763 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05297448 |
| Rifaximin SSD | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05297448 |
| Placebo | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05297448 |
| Rifaximin SSD | Other | Phase PHASE3 | Hepatic Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05297448 |
| 100 mg/mL Virazole | Other | Phase PHASE1 | COVID19 | WITHDRAWN | NCT04356677 |
| 50 mg/mL Virazole | Other | Phase PHASE1 | COVID19 | WITHDRAWN | NCT04356677 |
| Placebo | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| High Dose Budesonide | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| Low Dose Budesonide | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| Placebo | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| High Dose Budesonide | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| Low Dose Budesonide | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT04314375 |
| Comparator Drug (non-biologic IL-17 inhibitors) | Drug | Preclinical | Psoriasis | ENROLLING_BY_INVITATION | NCT03254667 |
| Brodalumab | Other | Preclinical | Psoriasis | ENROLLING_BY_INVITATION | NCT03254667 |
| Brodalumab | Other | Phase PHASE4 | Psoriasis | ACTIVE_NOT_RECRUITING | NCT03240809 |
| Placebo | Other | Phase PHASE4 | Major Depressive Disorder | NOT_YET_RECRUITING | NCT02129751 |
| bupropion hydrobromide | Other | Phase PHASE4 | Major Depressive Disorder | NOT_YET_RECRUITING | NCT02129751 |
| Matching placebo rectal foam | Other | Phase PHASE4 | Ulcerative Colitis | NOT_YET_RECRUITING | NCT05976802 |
| Low dose budesonide rectal foam | Other | Phase PHASE4 | Ulcerative Colitis | NOT_YET_RECRUITING | NCT05976802 |
| High dose budesonide rectal foam | Other | Phase PHASE4 | Ulcerative Colitis | NOT_YET_RECRUITING | NCT05976802 |
| Miebo | Other | Phase PHASE4 | Dry Eye | COMPLETED | NCT06309953 |
| Epiduo® Forte Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04892706 |
| IDP-126 Vehicle Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04892706 |
| IDP-126 Gel | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04892706 |
| Bryhali | Other | Phase PHASE3 | Acne Keloidalis Nuchae | TERMINATED | NCT05608499 |
| Placebo | Other | Phase PHASE3 | Acne Keloidalis Nuchae | TERMINATED | NCT05608499 |
| Duobrii | Other | Phase PHASE3 | Acne Keloidalis Nuchae | TERMINATED | NCT05608499 |
| enVista MX60E monofocal IOL | Other | Approved | Cataract | ACTIVE_NOT_RECRUITING | NCT06333015 |
| enVista Beyond EY (EDF) IOL | Other | Approved | Cataract | ACTIVE_NOT_RECRUITING | NCT06333015 |
| enVista MX60E monofocal IOL | Other | Approved | Cataract | ACTIVE_NOT_RECRUITING | NCT06333015 |
| enVista Beyond EY (EDF) IOL | Other | Approved | Cataract | ACTIVE_NOT_RECRUITING | NCT06333015 |
| REVIVE samfilcon B custom toric contact lenses | Other | Preclinical | Astigmatism | NOT_YET_RECRUITING | NCT06785194 |
| Lifitegrast/perfluorohexyloctane (PFHO) | Other | Phase PHASE3 | Dry Eye Disease | WITHDRAWN | NCT07111013 |
| Lifitegrast/perfluorohexyloctane (PFHO) | Other | Phase PHASE3 | Dry Eye Disease | WITHDRAWN | NCT07111013 |
| Thermage FLX | Other | Approved | Wrinkle | RECRUITING | NCT07187297 |
| Perfluorohexyloctane ophthalmic solution | Other | Phase PHASE4 | Dry Eye | COMPLETED | NCT07054606 |
| Matching placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT03596905 |
| Plecanatide | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT03596905 |
| TENEO 317 Model 2 excimer laser | Other | Approved | Hyperopia | ACTIVE_NOT_RECRUITING | NCT05264623 |
| TENEO 317 Model 2 excimer laser | Other | Approved | Hyperopia | ACTIVE_NOT_RECRUITING | NCT05264623 |
| BL1332 ophthalmic vehicle | Other | Phase PHASE1 | Ocular Pain | ACTIVE_NOT_RECRUITING | NCT06978244 |
| BL1332 ophthalmic solution | Other | Phase PHASE1 | Ocular Pain | ACTIVE_NOT_RECRUITING | NCT06978244 |
| Fraxel® FTX Laser System | Other | Approved | Skin Resurfacing | ACTIVE_NOT_RECRUITING | NCT07214272 |
| Vehicle | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07128628 |
| Perfluorohexyloctane | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07128628 |
| Lifitegrast | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07128628 |
| Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | Other | Phase PHASE2 | Dry Eye Disease | RECRUITING | NCT07128628 |
| Xiidra (Lifitegrast ophthalmic solution) 5% | Other | Preclinical | Glaucoma | RECRUITING | NCT04354545 |
| (Xiidra®) Lifitegrast Ophthalmic Solution 5.0% | Other | Phase PHASE4 | Ocular Surface Disease | NOT_YET_RECRUITING | NCT07490535 |
| clindamycin phosphate, adapalene and benzoyl peroxide | Other | Preclinical | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT07205107 |
| clindamycin phosphate, adapalene and benzoyl peroxide | Other | Preclinical | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT07205107 |
| Placebo | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Larsucosterol | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Placebo | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Larsucosterol | Other | Phase PHASE3 | Hepatitis | RECRUITING | NCT07428538 |
| Placebo | Other | Phase PHASE1 | Dementia Alzheimer Type | RECRUITING | NCT06718686 |
| Rifaximin SSD 40 mg IR tablet | Other | Phase PHASE1 | Dementia Alzheimer Type | RECRUITING | NCT06718686 |
| Placebo | Other | Phase PHASE1 | Dementia Alzheimer Type | RECRUITING | NCT06718686 |
| Rifaximin SSD 40 mg IR tablet | Other | Phase PHASE1 | Dementia Alzheimer Type | RECRUITING | NCT06718686 |
| Dental exam and periodontal cleaning if needed | Other | Preclinical | Cirrhosis | ACTIVE_NOT_RECRUITING | NCT06052150 |
| Dental exam and periodontal cleaning if needed | Other | Preclinical | Cirrhosis | ACTIVE_NOT_RECRUITING | NCT06052150 |
| IDP-118 Lotion | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT03988439 |
| CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. | Other | Phase PHASE4 | Acne Vulgaris | NOT_YET_RECRUITING | NCT07524946 |
| BCMC lens | Other | Approved | Myopia | RECRUITING | NCT07511387 |
Total products: 1069